FEED Validator

for Atom and RSS and KML

Congratulations!

This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

line 7, column 299: Self reference doesn't match document location [help]

... bCw41XEP22XBMPcA09_yeH4Yib" rel="self"/>
                                             ^

line 18, column 0: content:encoded should not contain xmlns:xlink attribute (153 occurrences) [help]
```
      <content:encoded><![CDATA[<div>Mol Neurobio ...
```
line 18, column 0: content:encoded should not contain xmlns:mml attribute (153 occurrences) [help]
```
      <content:encoded><![CDATA[<div>Mol Neurobio ...
```
line 18, column 0: content:encoded should not contain xmlns:p1 attribute (153 occurrences) [help]
```
      <content:encoded><![CDATA[<div>Mol Neurobio ...
```
line 32, column 6: An item should not include both pubDate and dc:date (50 occurrences) [help]
```
      <dc:date>2024-05-07</dc:date>
      ^
```

Source: http://www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib

<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
<channel>
<title>ischemic stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&utm_source=Feedvalidator&utm_medium=rss&v=2.18.0.post9+e462414&ff=20240507172821&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib</link>
<description>ischemic stroke: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&utm_source=Feedvalidator&utm_medium=rss&v=2.18.0.post9+e462414&ff=20240507172821&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib" rel="self"/>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastBuildDate>Tue, 07 May 2024 21:28:22 +0000</lastBuildDate>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Transcriptome Analysis Reveals Dynamic Microglial-Induced A1 Astrocyte Reactivity via C3/C3aR/NF-kappaB Signaling After Ischemic Stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38713438/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Microglia and astrocytes are key players in neuroinflammation and ischemic stroke. A1 astrocytes are a subtype of astrocytes that are extremely neurotoxic and quickly kill neurons. Although the detrimental A1 astrocytes are present in many neurodegenerative diseases and are considered to accelerate neurodegeneration, their role in the pathophysiology of ischemic stroke is poorly understood. Here, we combined RNA-seq, molecular and immunological techniques, and behavioral tests to investigate the...</description>
<content:encoded><![CDATA[<div>Mol Neurobiol. 2024 May 7. doi: 10.1007/s12035-024-04210-8. Online ahead of print.ABSTRACTMicroglia and astrocytes are key players in neuroinflammation and ischemic stroke. A1 astrocytes are a subtype of astrocytes that are extremely neurotoxic and quickly kill neurons. Although the detrimental A1 astrocytes are present in many neurodegenerative diseases and are considered to accelerate neurodegeneration, their role in the pathophysiology of ischemic stroke is poorly understood. Here, we combined RNA-seq, molecular and immunological techniques, and behavioral tests to investigate the role of A1 astrocytes in the pathophysiology of ischemic stroke. We found that astrocyte phenotypes change from a beneficial A2 type in the acute phase to a detrimental A1 type in the chronic phase following ischemic stroke. The activated microglial IL1α, TNF, and C1q prompt commitment of A1 astrocytes. Inhibition of A1 astrocytes induction attenuates reactive gliosis and ameliorates morphological and functional defects following ischemic stroke. The crosstalk between astrocytic C3 and microglial C3aR contributes to the formation of A1 astrocytes and morphological and functional defects. In addition, NF-κB is activated following ischemic stroke and governs the formation of A1 astrocytes via direct targeting of inflammatory cytokines and chemokines. Taken together, we discovered that A2 astrocytes and A1 astrocytes are enriched in the acute and chronic phases of ischemic stroke respectively, and that the C3/C3aR/NF-κB signaling leads to A1 astrocytes induction. Therefore, the C3/C3aR/NF-κB signaling is a novel therapeutic target for ischemic stroke treatment.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713438/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38713438</a> | DOI:<a href=https://doi.org/10.1007/s12035-024-04210-8>10.1007/s12035-024-04210-8</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38713438</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Song Wang</dc:creator>
<dc:creator>Yuhualei Pan</dc:creator>
<dc:creator>Chengjie Zhang</dc:creator>
<dc:creator>Yushang Zhao</dc:creator>
<dc:creator>Huan Wang</dc:creator>
<dc:creator>Huixuan Ma</dc:creator>
<dc:creator>Jinmei Sun</dc:creator>
<dc:creator>Song Zhang</dc:creator>
<dc:creator>Jingyi Yao</dc:creator>
<dc:creator>Dan Xie</dc:creator>
<dc:creator>Yongbo Zhang</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Molecular neurobiology</dc:source>
<dc:title>Transcriptome Analysis Reveals Dynamic Microglial-Induced A1 Astrocyte Reactivity via C3/C3aR/NF-kappaB Signaling After Ischemic Stroke</dc:title>
<dc:identifier>pmid:38713438</dc:identifier>
<dc:identifier>doi:10.1007/s12035-024-04210-8</dc:identifier>
</item>
<item>
<title>Regulating NCOA4-Mediated Ferritinophagy for Therapeutic Intervention in Cerebral Ischemia-Reperfusion Injury</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38713437/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Ischemic stroke presents a global health challenge, necessitating an in-depth comprehension of its pathophysiology and therapeutic strategies. While reperfusion therapy salvages brain tissue, it also triggers detrimental cerebral ischemia-reperfusion injury (CIRI). In our investigation, we observed the activation of nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy in an oxygen-glucose deprivation/reoxygenation (OGD/R) model using HT22 cells (P < 0.05). This activation contributed...</description>
<content:encoded><![CDATA[<div>Neurochem Res. 2024 May 7. doi: 10.1007/s11064-024-04146-4. Online ahead of print.ABSTRACTIschemic stroke presents a global health challenge, necessitating an in-depth comprehension of its pathophysiology and therapeutic strategies. While reperfusion therapy salvages brain tissue, it also triggers detrimental cerebral ischemia-reperfusion injury (CIRI). In our investigation, we observed the activation of nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy in an oxygen-glucose deprivation/reoxygenation (OGD/R) model using HT22 cells (P < 0.05). This activation contributed to oxidative stress (P < 0.05), enhanced autophagy (P < 0.05) and cell death (P < 0.05) during CIRI. Silencing NCOA4 effectively mitigated OGD/R-induced damage (P < 0.05). These findings suggested that targeting NCOA4-mediated ferritinophagy held promise for preventing and treating CIRI. Subsequently, we substantiated the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway effectively regulated the NCOA4-mediated ferritinophagy, by applying the cGAS inhibitor RU.521 and performing NCOA4 overexpression (P < 0.05). Suppressing the cGAS-STING pathway efficiently curtailed ferritinophagy (P < 0.05), oxidative stress (P < 0.05), and cell damage (P < 0.05) of CIRI, while NCOA4 overexpression could alleviate this effect (P < 0.05). Finally, we elucidated the specific molecular mechanism underlying the protective effect of the iron chelator deferoxamine (DFO) on CIRI. Our findings revealed that DFO alleviated hypoxia-reoxygenation injury in HT22 cells through inhibiting NCOA4-mediated ferritinophagy and reducing ferrous ion levels (P < 0.05). However, the protective effects of DFO were counteracted by cGAS overexpression (P < 0.05). In summary, our results indicated that the activation of the cGAS-STING pathway intensified cerebral damage during CIRI by inducing NCOA4-mediated ferritinophagy. Administering the iron chelator DFO effectively attenuated NCOA4-induced ferritinophagy, thereby alleviating CIRI. Nevertheless, the role of the cGAS-STING pathway in CIRI regulation likely involves intricate mechanisms, necessitating further validation in subsequent investigations.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713437/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38713437</a> | DOI:<a href=https://doi.org/10.1007/s11064-024-04146-4>10.1007/s11064-024-04146-4</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38713437</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Yanan Li</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Xue Qi</dc:creator>
<dc:creator>Su Wang</dc:creator>
<dc:creator>Wenqin Song</dc:creator>
<dc:creator>Ting Li</dc:creator>
<dc:creator>Wenwei Gao</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Neurochemical research</dc:source>
<dc:title>Regulating NCOA4-Mediated Ferritinophagy for Therapeutic Intervention in Cerebral Ischemia-Reperfusion Injury</dc:title>
<dc:identifier>pmid:38713437</dc:identifier>
<dc:identifier>doi:10.1007/s11064-024-04146-4</dc:identifier>
</item>
<item>
<title>Open surgical treatment for carotid stenoses</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38713222/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Open surgical therapy, as a crucial treatment method, is increasingly important, especially as an emergency intervention. Its role in modern medicine emphasizes the urgency of prioritizing this life-saving procedure in healthcare and making it widely available.</description>
<content:encoded><![CDATA[<div>Radiologie (Heidelb). 2024 May 7. doi: 10.1007/s00117-024-01307-y. Online ahead of print.ABSTRACTBACKGROUND: Globally, stroke is considered the second most common cause of death. According to the German Federal Statistical Office, 33.6% of mortality was due to cardiovascular diseases, making them the most prevalent cause of death.PROBLEM: Specifically, cerebral infarctions were recorded as the cause in over 16,000 cases. These figures underscore the significant role that cerebrovascular diseases play in Germany's mortality statistics. Notably, about 80% of strokes are ischemic. Moreover, one-fifth of all strokes result from extracranial carotid stenosis. The increase in stroke risk with advancing age, especially among men, is particularly striking. This trend highlights the growing importance of efficient stroke prevention and treatment in an aging society.CONCLUSION: Open surgical therapy, as a crucial treatment method, is increasingly important, especially as an emergency intervention. Its role in modern medicine emphasizes the urgency of prioritizing this life-saving procedure in healthcare and making it widely available.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713222/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38713222</a> | DOI:<a href=https://doi.org/10.1007/s00117-024-01307-y>10.1007/s00117-024-01307-y</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38713222</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roushanak Shayesteh-Kheslat</dc:creator>
<dc:creator>Mario Lescan</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Radiologie (Heidelberg, Germany)</dc:source>
<dc:title>Open surgical treatment for carotid stenoses</dc:title>
<dc:identifier>pmid:38713222</dc:identifier>
<dc:identifier>doi:10.1007/s00117-024-01307-y</dc:identifier>
</item>
<item>
<title>A prospective multicenter feasibility study of a miniaturized implantable continuous flow ventricular assist device in smaller children with heart failure</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38713124/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: The Jarvik 2015 LVAD appears to hold important promise as an implantable continuous flow device for smaller children that may support hospital discharge. The FDA has approved the device to proceed to a 22-subject pivotal trial. Whether this device will survive to commercialization remains unclear because of the financial challenges faced by industry seeking to develop pediatric medical devices. (Supported by NIH/NHLBI HHS Contract N268201200001I, clinicaltrials.gov 02954497).</description>
<content:encoded><![CDATA[<div>J Heart Lung Transplant. 2024 Apr 30:S1053-2498(24)00042-1. doi: 10.1016/j.healun.2024.02.003. Online ahead of print.ABSTRACTBACKGROUND: There is no FDA-approved left ventricular assist device (LVAD) for smaller children permitting routine hospital discharge. Smaller children supported with LVADs typically remain hospitalized for months awaiting heart transplant-a major burden for families and a challenge for hospitals. We describe the initial outcomes of the Jarvik 2015, a miniaturized implantable continuous flow LVAD, in the NHLBI-funded Pumps for Kids, Infants, and Neonates (PumpKIN) study, for bridge-to-heart transplant.METHODS: Children weighing 8 to 30 kg with severe systolic heart failure and failing optimal medical therapy were recruited at 7 centers in the United States. Patients with severe right heart failure and single-ventricle congenital heart disease were excluded. The primary feasibility endpoint was survival to 30 days without severe stroke or non-operational device failure.RESULTS: Of 7 children implanted, the median age was 2.2 (range 0.7, 7.1) years, median weight 10 (8.2 to 20.7) kilograms; 86% had dilated cardiomyopathy; 29% were INTERMACS profile 1. The median duration of Jarvik 2015 support was 149 (range 5 to 188) days where all 7 children survived including 5 to heart transplant, 1 to recovery, and 1 to conversion to a paracorporeal device. One patient experienced an ischemic stroke on day 53 of device support in the setting of myocardial recovery. One patient required ECMO support for intractable ventricular arrhythmias and was eventually transplanted from paracorporeal biventricular VAD support. The median pump speed was 1600 RPM with power ranging from 1-4 Watts. The median plasma free hemoglobin was 19, 30, 19 and 30 mg/dL at 7, 30, 90 and 180 days or time of explant, respectively. All patients reached the primary feasibility endpoint. Patient-reported outcomes with the device were favorable with respect to participation in a full range of activities. Due to financial issues with the manufacturer, the study was suspended after consent of the eighth patient.CONCLUSION: The Jarvik 2015 LVAD appears to hold important promise as an implantable continuous flow device for smaller children that may support hospital discharge. The FDA has approved the device to proceed to a 22-subject pivotal trial. Whether this device will survive to commercialization remains unclear because of the financial challenges faced by industry seeking to develop pediatric medical devices. (Supported by NIH/NHLBI HHS Contract N268201200001I, clinicaltrials.gov 02954497).PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713124/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38713124</a> | DOI:<a href=https://doi.org/10.1016/j.healun.2024.02.003>10.1016/j.healun.2024.02.003</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38713124</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher S Almond</dc:creator>
<dc:creator>Ryan Davies</dc:creator>
<dc:creator>Iki Adachi</dc:creator>
<dc:creator>Marc Richmond</dc:creator>
<dc:creator>Sabrina Law</dc:creator>
<dc:creator>Hari Tunuguntla</dc:creator>
<dc:creator>Chad Mao</dc:creator>
<dc:creator>Fawwaz Shaw</dc:creator>
<dc:creator>Jodie Lantz</dc:creator>
<dc:creator>Peter D Wearden</dc:creator>
<dc:creator>Lori C Jordan</dc:creator>
<dc:creator>Rebecca N Ichord</dc:creator>
<dc:creator>Kristin Burns</dc:creator>
<dc:creator>Victor Zak</dc:creator>
<dc:creator>Ashley Magnavita</dc:creator>
<dc:creator>Selena Gonzales</dc:creator>
<dc:creator>Jennifer Conway</dc:creator>
<dc:creator>Aamir Jeewa</dc:creator>
<dc:creator>D 'Andrea Freemon</dc:creator>
<dc:creator>Mario Stylianou</dc:creator>
<dc:creator>Lynn Sleeper</dc:creator>
<dc:creator>John C Dykes</dc:creator>
<dc:creator>Michael Ma</dc:creator>
<dc:creator>Francis Fynn-Thompson</dc:creator>
<dc:creator>Angela Lorts</dc:creator>
<dc:creator>David Morales</dc:creator>
<dc:creator>Christina Vanderpluym</dc:creator>
<dc:creator>Kurt Dasse</dc:creator>
<dc:creator>M Patricia Massicotte</dc:creator>
<dc:creator>Robert Jaquiss</dc:creator>
<dc:creator>William T Mahle</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</dc:source>
<dc:title>A prospective multicenter feasibility study of a miniaturized implantable continuous flow ventricular assist device in smaller children with heart failure</dc:title>
<dc:identifier>pmid:38713124</dc:identifier>
<dc:identifier>doi:10.1016/j.healun.2024.02.003</dc:identifier>
</item>
<item>
<title>Hyperglycaemia perturbs blood-brain barrier integrity through its effects on endothelial cell characteristics and function</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38712515/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Breakdown of blood-brain barrier (BBB) represents a key pathology in hyperglycemia-mediated cerebrovascular damage after an ischemic stroke. As changes in the level and nature of vasoactive agents released by endothelial cells (ECs) may contribute to BBB dysfunction, this study first explored the specific impact of hyperglycemia on EC characteristics and secretome. It then assessed whether secretome obtained from ECs subjected to normoglycaemia or hyperglycemia might regulate pericytic cytokine...</description>
<content:encoded><![CDATA[<div>Tissue Barriers. 2024 May 7:2350821. doi: 10.1080/21688370.2024.2350821. Online ahead of print.ABSTRACTBreakdown of blood-brain barrier (BBB) represents a key pathology in hyperglycemia-mediated cerebrovascular damage after an ischemic stroke. As changes in the level and nature of vasoactive agents released by endothelial cells (ECs) may contribute to BBB dysfunction, this study first explored the specific impact of hyperglycemia on EC characteristics and secretome. It then assessed whether secretome obtained from ECs subjected to normoglycaemia or hyperglycemia might regulate pericytic cytokine profile differently. Using a triple cell culture model of human BBB, composed of brain microvascular EC (BMEC), astrocytes and pericytes, this study showed that exposure to hyperglycemia (25 mM D-glucose) for 72 h impaired the BBB integrity and function as evidenced by decreases in transendothelial electrical resistance and increases in paracellular flux of sodium fluorescein. Dissolution of zonula occludens-1, a tight junction protein, and appearance of stress fibers appeared to play a key role in this pathology. Despite elevations in angiogenin, endothelin-1, interleukin-8 and basic fibroblast growth factor levels and a decrease in placental growth factor levels in BMEC subjected to hyperglycemia vs normoglycaemia (5.5 mM D-glucose), tubulogenic capacity of BMECs remained similar in both settings. Similarly, pericytes subjected to secretome obtained from hyperglycemic BMEC released higher quantities of macrophage migration inhibitory factor and serpin and lower quantities of monocyte chemoattractant protein-1, intercellular adhesion molecule, interleukin-6 and interleukin-8. Taken together these findings indicate the complexity of the mechanisms leading to BBB disruption in hyperglycemic settings and emphasize the importance of endothelial cell-pericyte axis in the development of novel therapeutic strategies.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38712515/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38712515</a> | DOI:<a href=https://doi.org/10.1080/21688370.2024.2350821>10.1080/21688370.2024.2350821</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38712515</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Arshad Hashmat</dc:creator>
<dc:creator>Jingyuan Ya</dc:creator>
<dc:creator>Rais Kadir</dc:creator>
<dc:creator>Mansour Alwjwaj</dc:creator>
<dc:creator>Ulvi Bayraktutan</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Tissue barriers</dc:source>
<dc:title>Hyperglycaemia perturbs blood-brain barrier integrity through its effects on endothelial cell characteristics and function</dc:title>
<dc:identifier>pmid:38712515</dc:identifier>
<dc:identifier>doi:10.1080/21688370.2024.2350821</dc:identifier>
</item>
<item>
<title>Risk of Ischemic Stroke in Relation to Helicobacter pylori Infection and Eradication Status: A Large-Scale Prospective Observational Cohort Study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38712396/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: : This finding suggests that HP eradication might not impact the risk of ischemic stroke. However, there was a trend showing that females potentially had a lower risk of ischemic stroke following HP eradication, though further investigation is required to establish definitive evidence.</description>
<content:encoded><![CDATA[<div>Gut Liver. 2024 May 7. doi: 10.5009/gnl230458. Online ahead of print.ABSTRACTBACKGROUND/AIMS: : A few studies have suggested the association between Helicobacter pylori (HP) infection and ischemic stroke. However, the impact of HP eradication on stroke risk has not been well evaluated. This study aimed to assess the influence of HP eradication on the incidence of ischemic stroke, considering the potential effect of sex.METHODS: : This prospective observational cohort study was conducted at Seoul National University Bundang Hospital, from May 2003 to February 2023, and involved gastroscopy-based HP testing. Propensity score (PS) matching was employed to ensure balanced groups by matching patients in the HP eradicated group (n=2,803) in a 3:1 ratio with patients in the HP non-eradicated group (n=960). Cox proportional hazard regression analysis was used to evaluate the risk of ischemic stroke.RESULTS: : Among 6,664 patients, multivariate analysis after PS matching indicated that HP eradication did not significantly alter the risk of ischemic stroke (hazard ratio, 0.531; 95% confidence interval, 0.221 to 1.270; p=0.157). Sex-specific subgroup analyses, both univariate and multivariate, did not yield statistically significant differences. However, Kaplan-Meier analysis revealed a potential trend: the females in the HP eradicated group exhibited a lower incidence of ischemic stroke than those in the HP non-eradicated group, although this did not reach statistical significance (p=0.057).CONCLUSIONS: : This finding suggests that HP eradication might not impact the risk of ischemic stroke. However, there was a trend showing that females potentially had a lower risk of ischemic stroke following HP eradication, though further investigation is required to establish definitive evidence.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38712396/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38712396</a> | DOI:<a href=https://doi.org/10.5009/gnl230458>10.5009/gnl230458</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38712396</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Eun-Bi Jeon</dc:creator>
<dc:creator>Nayoung Kim</dc:creator>
<dc:creator>Beom Joon Kim</dc:creator>
<dc:creator>In-Chang Hwang</dc:creator>
<dc:creator>Sang Bin Kim</dc:creator>
<dc:creator>Ji-Hyun Kim</dc:creator>
<dc:creator>Yonghoon Choi</dc:creator>
<dc:creator>Yu Kyung Jun</dc:creator>
<dc:creator>Hyuk Yoon</dc:creator>
<dc:creator>Cheol Min Shin</dc:creator>
<dc:creator>Young Soo Park</dc:creator>
<dc:creator>Dong Ho Lee</dc:creator>
<dc:creator>Soyeon Ahn</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Gut and liver</dc:source>
<dc:title>Risk of Ischemic Stroke in Relation to Helicobacter pylori Infection and Eradication Status: A Large-Scale Prospective Observational Cohort Study</dc:title>
<dc:identifier>pmid:38712396</dc:identifier>
<dc:identifier>doi:10.5009/gnl230458</dc:identifier>
</item>
<item>
<title>Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711560/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Visit-to-visit renal function variability is independently associated with adverse clinical outcomes in TIA/ischemic stroke patients with AF. Further large-scale studies are needed to validate our results.</description>
<content:encoded><![CDATA[<div>Front Neurol. 2024 Apr 22;15:1294022. doi: 10.3389/fneur.2024.1294022. eCollection 2024.ABSTRACTBACKGROUND: Although renal dysfunction is associated with adverse clinical outcomes in patients with atrial fibrillation (AF) following stroke, the impact of renal function variability is unclear.AIM: This study aimed to assess the association between renal function variability and various adverse clinical outcomes in patients with transient ischemic attack (TIA)/ischemic stroke and atrial fibrillation (AF).METHODS: We conducted a population-based study and retrospectively identified patients hospitalized with a diagnosis of TIA/ischemic stroke and AF during 2016-2020 using the Clinical Data Analysis and Reporting System of Hong Kong. Serial serum creatinine tested upon the onset of TIA/ischemic stroke and during their subsequent follow-up was collected. Renal function variability was calculated using the coefficient of variation of the estimated glomerular filtration rate (eGFR). Clinical endpoints that occurred during the study period were captured and included ischemic stroke/systemic embolism, intracerebral hemorrhage (ICH), total bleeding, major adverse cardiovascular events (MACE), cardiovascular, non-cardiovascular, and all-cause mortality. Competing risk regression and Cox proportional hazard regression models were used to assess the associations of renal function variability with the outcomes of interest.RESULTS: A total of 3,809 patients (mean age 80 ± 10 years, 43% men) who satisfied the inclusion and exclusion criteria were followed up for a mean of 2.5 ± 1.5 years (9,523 patient-years). The mean eGFR was 66 ± 22 mL/min/1.73 m2 at baseline, and the median number of renal function tests per patient during the follow-up period was 20 (interquartile range 11-35). After accounting for potential confounders, a greater eGFR variability was associated with increased risks of recurrent ischemic stroke/systemic embolism [fully adjusted subdistribution hazard ratio 1.11, 95% confidence interval (CI) 1.03-1.20], ICH (1.17, 1.01-1.36), total bleeding (1.13, 1.06-1.21), MACE (1.22, 1.15-1.30), cardiovascular (1.49, 1.32-1.69), non-cardiovascular (1.43, 1.35-1.52), and all-cause mortality (fully adjusted hazard ratio 1.44, 1.39-1.50).CONCLUSION: Visit-to-visit renal function variability is independently associated with adverse clinical outcomes in TIA/ischemic stroke patients with AF. Further large-scale studies are needed to validate our results.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711560/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711560</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11071668/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11071668</a> | DOI:<a href=https://doi.org/10.3389/fneur.2024.1294022>10.3389/fneur.2024.1294022</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711560</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiao Wang</dc:creator>
<dc:creator>Chun-Fung Sin</dc:creator>
<dc:creator>Kay-Cheong Teo</dc:creator>
<dc:creator>William C Y Leung</dc:creator>
<dc:creator>Yuen-Kwun Wong</dc:creator>
<dc:creator>Roxanna K C Liu</dc:creator>
<dc:creator>Joshua W Fok</dc:creator>
<dc:creator>Bonaventure Y Ip</dc:creator>
<dc:creator>Hon Hang Kwan</dc:creator>
<dc:creator>Tsz Ching Lee</dc:creator>
<dc:creator>Bun Sheng</dc:creator>
<dc:creator>Edwin Kin-Keung Yip</dc:creator>
<dc:creator>Desmond Y H Yap</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Kui-Kai Lau</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Frontiers in neurology</dc:source>
<dc:title>Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation</dc:title>
<dc:identifier>pmid:38711560</dc:identifier>
<dc:identifier>pmc:PMC11071668</dc:identifier>
<dc:identifier>doi:10.3389/fneur.2024.1294022</dc:identifier>
</item>
<item>
<title>Serial ASPECTS to predict stroke-associated pneumonia after thrombolysis in patients with acute ischemic stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711555/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: 24-h NCCT-ASPECTS outperformed both baseline ASPECTS and change in ASPECTS for predicting SAP. Notably, 24-h ASPECTS, with a cut-off value of ≤6, exhibited good predictive performance and emerged as the better predictor for SAP.</description>
<content:encoded><![CDATA[<div>Front Neurol. 2024 Apr 22;15:1364125. doi: 10.3389/fneur.2024.1364125. eCollection 2024.ABSTRACTBACKGROUND: Stroke-associated pneumonia (SAP) is a serious complication in stroke patients, significantly increasing mortality. The Alberta Stroke Program Early CT Score (ASPECTS) is a recognized predictor of acute ischemic stroke outcomes. We aimed to investigate the performance of serial ASPECTS assessments (baseline ASPECTS, 24-h ASPECTS, and change in ASPECTS) for predicting SAP in patients with thrombolyzed acute anterior circulation ischemic stroke (AACIS).MATERIALS: A retrospective observational cohort study of adult patients with thrombolyzed AACIS was conducted. Baseline and 24-h ASPECTS using non-contrast computed tomography (NCCT), complications of stroke, including SAP and swallowing dysfunction using the Modified Water Swallowing test, were collected. Baseline and 24-h ASPECTS were evaluated by a certified neurologist and neuroradiologist. The predictive performance was determined based on the receiver operating characteristic curve (ROC). Multivariable logistic regression analyses were employed to assess the impact of serial ASPECTS assessment on predicting SAP.RESULTS: Of the 345 patients with thrombolyzed AACIS in our study, 18.4% (64/345) experienced SAP. The patients' median age was 62 years [interquartile range (IQR): 52-73], with 53.4% being male. The median NIHSS score was 11 points (IQR: 8-17). The ROC analysis revealed areas under the curve for predicting SAP with baseline ASPECTS, 24-h ASPECTS, and change in ASPECTS were 0.75 (95% CI, 0.69-0.82), 0.84 (95% CI, 0.79-0.89), and 0.82 (95% CI, 0.76-0.87), respectively. Of the three measures, 24-h ASPECTS was a better predictor of SAP (odds ratio: 5.33, 95%CI: 2.08-13.67, p < 0.001) and had a higher sensitivity (0.84 [95%CI, 0.74-0.92]) and specificity (0.79 [95%CI, 0.74-0.84]) than both baseline ASPECTS and change in ASPECTS.CONCLUSION: 24-h NCCT-ASPECTS outperformed both baseline ASPECTS and change in ASPECTS for predicting SAP. Notably, 24-h ASPECTS, with a cut-off value of ≤6, exhibited good predictive performance and emerged as the better predictor for SAP.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711555/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711555</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11071176/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11071176</a> | DOI:<a href=https://doi.org/10.3389/fneur.2024.1364125>10.3389/fneur.2024.1364125</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711555</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarawut Krongsut</dc:creator>
<dc:creator>Atiwat Soontornpun</dc:creator>
<dc:creator>Niyada Anusasnee</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Frontiers in neurology</dc:source>
<dc:title>Serial ASPECTS to predict stroke-associated pneumonia after thrombolysis in patients with acute ischemic stroke</dc:title>
<dc:identifier>pmid:38711555</dc:identifier>
<dc:identifier>pmc:PMC11071176</dc:identifier>
<dc:identifier>doi:10.3389/fneur.2024.1364125</dc:identifier>
</item>
<item>
<title>Relationship between fibroblast growth factor in plasma and carotid plaque neovascularization: a pilot study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711510/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: This pilot study suggest the potential of FGF-23 as a valuable marker for neovascularization and atherosclerotic carotid plaque instability as a risk factor for ischemic stroke. Further research involving larger cohorts and prospective data is necessary to understand FGF-23's role in this context comprehensively.</description>
<content:encoded><![CDATA[<div>Front Immunol. 2024 Apr 22;15:1385377. doi: 10.3389/fimmu.2024.1385377. eCollection 2024.ABSTRACTBACKGROUND: Unstable atherosclerotic carotid plaques with intraplaque neovascularization (IPN) carry a substantial risk for ischemic stroke. Conventional ultrasound methods fall short in detecting IPN, where superb microvascular imaging (SMI) has emerged as a promising tool for both visualizing and quantification. High levels of fibroblast growth factor 23 (FGF-23) have, in observational studies, been suggested as related to cardiovascular morbidity and mortality. The association of FGF-23 to atherosclerotic carotid plaque instability remains relatively unexplored.METHODS: A cohort of twenty-nine patients with ≥50% atherosclerotic carotid stenosis underwent conventional carotid ultrasound, SMI, and blood tests, including measurement of FGF-23 in plasma. Nineteen patients were characterized as symptomatic and ten as asymptomatic.RESULTS: Our major findings were: i) Higher FGF-23 levels were strongly correlated with increased SMI-assessed IPN. ii) Neo-vessel count recorded by quantitative SMI was positively correlated to increased FGF-23 levels, but not with basic FGF levels. (iii) In contrast, traditional risk factors for plaque instability exhibited no noteworthy associations with SMI-assessed IPN or with FGF-23 levels.CONCLUSION: This pilot study suggest the potential of FGF-23 as a valuable marker for neovascularization and atherosclerotic carotid plaque instability as a risk factor for ischemic stroke. Further research involving larger cohorts and prospective data is necessary to understand FGF-23's role in this context comprehensively.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711510/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711510</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11070475/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11070475</a> | DOI:<a href=https://doi.org/10.3389/fimmu.2024.1385377>10.3389/fimmu.2024.1385377</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711510</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mahtab Zamani</dc:creator>
<dc:creator>Karolina Skagen</dc:creator>
<dc:creator>Beate Lindberg</dc:creator>
<dc:creator>Vigdis Bjerkeli</dc:creator>
<dc:creator>Pål Aukrust</dc:creator>
<dc:creator>Bente Halvorsen</dc:creator>
<dc:creator>Mona Skjelland</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Frontiers in immunology</dc:source>
<dc:title>Relationship between fibroblast growth factor in plasma and carotid plaque neovascularization: a pilot study</dc:title>
<dc:identifier>pmid:38711510</dc:identifier>
<dc:identifier>pmc:PMC11070475</dc:identifier>
<dc:identifier>doi:10.3389/fimmu.2024.1385377</dc:identifier>
</item>
<item>
<title>Epidemiology of transient ischemic attack in the normandy stroke population-based study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711259/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: We found that the use of the tissue-based definition of TIA resulted in a 27.5% reduction in incidence as compared to the time-based definition, but had no impact on the 90-day stroke rate. The burden of TIA remains high, and is likely to increase as the population ages.</description>
<content:encoded><![CDATA[<div>Eur Stroke J. 2024 May 6:23969873241251722. doi: 10.1177/23969873241251722. Online ahead of print.ABSTRACTINTRODUCTION: Transient ischemic attack (TIA) is a frequent neurological emergency which management and definition have changed radically over the last 15 years. However, recent epidemiological studies of TIA are scarce. We report here on the impact of the shift from a time-based to a tissue-based definition of TIA on its incidence and risk of recurrence in a new population-based cohort with a high rate of patients investigated by MRI.MATERIALS AND METHODS: We prospectively included all TIAs that occurred between May 2017 and May 2021 from the Normandy Stroke Study, a population-based registry using multiple overlapping sources for exhaustive case identification in Caen la Mer area. TIAs were classified as either time-based (symptoms <24 h) or tissue-based (<24 h and no lesion on brain imaging). Attack and incidence rates were calculated, as was the 90-day ischemic stroke rate.RESULTS: Five hundred and sixty-seven TIAs (549 single patients) were included, with 80.6% having a brain MRI. Four hundred and ten (72.3%) met the definition of tissue-based TIA. The age standardized attack (to the 2013 European population) rate was 39.5 (95% CI 35.7-43.5) and the age-standardized incidence rate (first ever cerebrovascular event) was 29.7 (95% CI 27.3-34.2). The overall recurrent stroke rate at 90 days was 2.7%, with no difference between patients with or without ischemic lesions on MRI.CONCLUSION: We found that the use of the tissue-based definition of TIA resulted in a 27.5% reduction in incidence as compared to the time-based definition, but had no impact on the 90-day stroke rate. The burden of TIA remains high, and is likely to increase as the population ages.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711259/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711259</a> | DOI:<a href=https://doi.org/10.1177/23969873241251722>10.1177/23969873241251722</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711259</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Romain Schneckenburger</dc:creator>
<dc:creator>Marion Boulanger</dc:creator>
<dc:creator>Ahmad Nehme</dc:creator>
<dc:creator>Marguerite Watrin</dc:creator>
<dc:creator>Gwendoline Le Du</dc:creator>
<dc:creator>Sophie Guettier</dc:creator>
<dc:creator>Lydia Guittet</dc:creator>
<dc:creator>Emmanuel Touzé</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European stroke journal</dc:source>
<dc:title>Epidemiology of transient ischemic attack in the normandy stroke population-based study</dc:title>
<dc:identifier>pmid:38711259</dc:identifier>
<dc:identifier>doi:10.1177/23969873241251722</dc:identifier>
</item>
<item>
<title>Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711254/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>BACKGROUND AND AIMS: Acute ischemic stroke (AIS) outcome prognostication remains challenging despite available prognostic models. We investigated whether a biomarker panel improves the predictive performance of established prognostic scores.</description>
<content:encoded><![CDATA[<div>Eur Stroke J. 2024 May 6:23969873241250272. doi: 10.1177/23969873241250272. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Acute ischemic stroke (AIS) outcome prognostication remains challenging despite available prognostic models. We investigated whether a biomarker panel improves the predictive performance of established prognostic scores.METHODS: We investigated the improvement in discrimination, calibration, and overall performance by adding five biomarkers (procalcitonin, copeptin, cortisol, mid-regional pro-atrial natriuretic peptide (MR-proANP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)) to the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) and age/NIHSS scores using data from two prospective cohort studies (SICFAIL, PREDICT) and one clinical trial (STRAWINSKI). Poor outcome was defined as mRS > 2 at 12 (SICFAIL, derivation dataset) or 3 months (PREDICT/STRAWINSKI, pooled external validation dataset).RESULTS: Among 412 SICFAIL participants (median age 70 years, quartiles 59-78; 63% male; median NIHSS score 3, quartiles 1-5), 29% had a poor outcome. Area under the curve of the ASTRAL and age/NIHSS were 0.76 (95% CI 0.71-0.81) and 0.77 (95% CI 0.73-0.82), respectively. Copeptin (0.79, 95% CI 0.74-0.84), NT-proBNP (0.80, 95% CI 0.76-0.84), and MR-proANP (0.79, 95% CI 0.75-0.84) significantly improved ASTRAL score's discrimination, calibration, and overall performance. Copeptin improved age/NIHSS model's discrimination, copeptin, MR-proANP, and NT-proBNP improved its calibration and overall performance. In the validation dataset (450 patients, median age 73 years, quartiles 66-81; 54% men; median NIHSS score 8, quartiles 3-14), copeptin was independently associated with various definitions of poor outcome and also mortality. Copeptin did not increase model's discrimination but it did improve calibration and overall model performance.DISCUSSION: Copeptin, NT-proBNP, and MR-proANP improved modest but consistently the predictive performance of established prognostic scores in patients with mild AIS. Copeptin was most consistently associated with poor outcome in patients with moderate to severe AIS, although its added prognostic value was less obvious.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711254/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711254</a> | DOI:<a href=https://doi.org/10.1177/23969873241250272>10.1177/23969873241250272</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711254</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Felipe A Montellano</dc:creator>
<dc:creator>Viktoria Rücker</dc:creator>
<dc:creator>Kathrin Ungethüm</dc:creator>
<dc:creator>Anna Penalba</dc:creator>
<dc:creator>Benjamin Hotter</dc:creator>
<dc:creator>Marina Giralt</dc:creator>
<dc:creator>Silke Wiedmann</dc:creator>
<dc:creator>Daniel Mackenrodt</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Stefan Frantz</dc:creator>
<dc:creator>Stefan Störk</dc:creator>
<dc:creator>William N Whiteley</dc:creator>
<dc:creator>Christoph Kleinschnitz</dc:creator>
<dc:creator>Andreas Meisel</dc:creator>
<dc:creator>Joan Montaner</dc:creator>
<dc:creator>Karl Georg Haeusler</dc:creator>
<dc:creator>Peter U Heuschmann</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European stroke journal</dc:source>
<dc:title>Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies</dc:title>
<dc:identifier>pmid:38711254</dc:identifier>
<dc:identifier>doi:10.1177/23969873241250272</dc:identifier>
</item>
<item>
<title>Robustness and classification capabilities of MRI radiomic features in identifying carotid plaque vulnerability</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711198/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: The combination of MRI-based radiomic features and lesion morphological and compositional parameters provided added value to the reference-standard risk assessment for carotid atherosclerosis. This may improve future risk stratification for individuals at risk of major adverse ischemic cerebrovascular events.</description>
<content:encoded><![CDATA[<div>Br J Radiol. 2024 May 7:tqae057. doi: 10.1093/bjr/tqae057. Online ahead of print.ABSTRACTOBJECTIVES: To assess how radiomic features may be combined with plaque morphological and compositional features identified by multi-contrast magnetic resonance imaging (MRI) to improve upon conventional risk assessment models in determining culprit lesions.METHODS: Fifty-five patients (mean age: 62.6; 35 males) with bilateral carotid stenosis who experienced transient ischaemic attack (TIA) or stroke were included from the CARE-II multi-centre carotid imaging trial (ClinicalTrials.gov Identifier: NCT02017756). They underwent MRI within 2 weeks of the event. Classification capability in distinguishing culprit lesions was assessed by machine learning. Repeatability and reproducibility of the results were investigated by assessing the robustness of the radiomic features.RESULTS: Radiomics combined with a relatively conventional plaque morphological and compositional metric-based model provided incremental value over a conventional model alone [area under curve (AUC), 0.819 ± 0.002 vs. 0.689 ± 0.019 respectively, p = 0.014]. The radiomic model alone also provided value over the conventional model [AUC, 0.805 ± 0.003 vs. 0.689 ± 0.019 respectively, p = 0.031]. T2-weighted imaging-based radiomic features had consistently higher robustness and classification capabilities compared with T1-weighted images. Higher-dimensional radiomic features outperformed first-order features. Grey Level Co-occurrence Matrix (GLCM), Grey Level Dependence Matrix (GLDM) and Grey Level Size Zone Matrix (GLSZM) sub-types were particularly useful in identifying textures which could detect vulnerable lesions.CONCLUSIONS: The combination of MRI-based radiomic features and lesion morphological and compositional parameters provided added value to the reference-standard risk assessment for carotid atherosclerosis. This may improve future risk stratification for individuals at risk of major adverse ischemic cerebrovascular events.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711198/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711198</a> | DOI:<a href=https://doi.org/10.1093/bjr/tqae057>10.1093/bjr/tqae057</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711198</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zakaria Meddings</dc:creator>
<dc:creator>Leonardo Rundo</dc:creator>
<dc:creator>Umar Sadat</dc:creator>
<dc:creator>Xihai Zhao</dc:creator>
<dc:creator>Zhongzhao Teng</dc:creator>
<dc:creator>Martin J Graves</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>The British journal of radiology</dc:source>
<dc:title>Robustness and classification capabilities of MRI radiomic features in identifying carotid plaque vulnerability</dc:title>
<dc:identifier>pmid:38711198</dc:identifier>
<dc:identifier>doi:10.1093/bjr/tqae057</dc:identifier>
</item>
<item>
<title>Association between physical activity changes and incident myocardial infarction after ischemic stroke: a nationwide population-based study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38711032/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: In this nationwide cohort study, commencing or sustaining physical activity after an IS corresponded to a diminished likelihood of subsequent MI development. Advocating physical activity in ambulatory stroke survivors could potentially attenuate the prospective risk of MI.</description>
<content:encoded><![CDATA[<div>BMC Public Health. 2024 May 6;24(1):1241. doi: 10.1186/s12889-024-18724-2.ABSTRACTBACKGROUND: The impact of changes in physical activity after ischemic stroke (IS) on the subsequent myocardial infarction (MI) risk is not fully understood. We aimed to investigate the effects of changes in physical activity on the risk of MI after acute IS using data from the Korean National Health Insurance Services Database.METHODS: 224,764 patients newly diagnosed with IS between 2010 and 2016 who underwent two serial biannual health checkups were included. The participants were divided into four categories according to changes in their physical activity: persistent non-exercisers, new exercisers, exercise dropouts, and exercise maintainers. The primary outcome was a new diagnosis of incident MI. Multivariable Cox proportional models were used to assess the effects of changes in exercise habits on the risk of MI.RESULTS: After a median of 4.25 years of follow-up, 6,611 (2.94%) MI cases were observed. After adjusting for confounders, new exercisers and exercise maintainers were significantly associated with a lower risk of incident MI than persistent non-exercisers (aHR, 0.849; 95% CI, 0.792-0.911; P-value < 0.001; and aHR, 0.746; 95% CI, 0.696-0.801; P-value < 0.001, respectively). Effects were consistent across sexes, more pronounced in those > 65 years. Notably, any level of physical activity after stroke was associated with a reduced MI risk compared to no exercise.CONCLUSIONS: In this nationwide cohort study, commencing or sustaining physical activity after an IS corresponded to a diminished likelihood of subsequent MI development. Advocating physical activity in ambulatory stroke survivors could potentially attenuate the prospective risk of MI.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38711032/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38711032</a> | DOI:<a href=https://doi.org/10.1186/s12889-024-18724-2>10.1186/s12889-024-18724-2</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38711032</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Dae Young Cheon</dc:creator>
<dc:creator>Kyung do Han</dc:creator>
<dc:creator>Yeon Jung Lee</dc:creator>
<dc:creator>Jeen Hwa Lee</dc:creator>
<dc:creator>Myung Soo Park</dc:creator>
<dc:creator>Do Young Kim</dc:creator>
<dc:creator>Jae Hyuk Choi</dc:creator>
<dc:creator>Sook Jin Lee</dc:creator>
<dc:creator>Kyung-Ho Yu</dc:creator>
<dc:creator>Seongwoo Han</dc:creator>
<dc:creator>Sunki Lee</dc:creator>
<dc:creator>Minwoo Lee</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>BMC public health</dc:source>
<dc:title>Association between physical activity changes and incident myocardial infarction after ischemic stroke: a nationwide population-based study</dc:title>
<dc:identifier>pmid:38711032</dc:identifier>
<dc:identifier>doi:10.1186/s12889-024-18724-2</dc:identifier>
</item>
<item>
<title>In mild ischemic stroke or high-risk TIA, DAPT started 72 h after onset reduced new stroke and increased bleeding at 90 d</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38710076/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Gao Y, Chen W, Pan Y, et al; INSPIRES Investigators. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023;389:2413-2424. 38157499.</description>
<content:encoded><![CDATA[<div>Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0029. Online ahead of print.ABSTRACTGao Y, Chen W, Pan Y, et al; INSPIRES Investigators. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023;389:2413-2424. 38157499.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38710076/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38710076</a> | DOI:<a href=https://doi.org/10.7326/J24-0029>10.7326/J24-0029</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38710076</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mark J Alberts</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Annals of internal medicine</dc:source>
<dc:title>In mild ischemic stroke or high-risk TIA, DAPT started 72 h after onset reduced new stroke and increased bleeding at 90 d</dc:title>
<dc:identifier>pmid:38710076</dc:identifier>
<dc:identifier>doi:10.7326/J24-0029</dc:identifier>
</item>
<item>
<title>Assessing the Efficacy of ChatGPT Versus Human Researchers in Identifying Relevant Studies on mHealth Interventions for Improving Medication Adherence in Patients With Ischemic Stroke When Conducting Systematic Reviews: Comparative Analysis</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38710069/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Our comparative analysis highlighted the strengths and limitations of both approaches. Ultimately, the choice between human researchers and ChatGPT depends on the specific requirements and objectives of each review, but the collaborative synergy of both approaches holds the potential to advance evidence-based research and decision-making in the health care field.</description>
<content:encoded><![CDATA[<div>JMIR Mhealth Uhealth. 2024 May 6;12:e51526. doi: 10.2196/51526.ABSTRACTBACKGROUND: ChatGPT by OpenAI emerged as a potential tool for researchers, aiding in various aspects of research. One such application was the identification of relevant studies in systematic reviews. However, a comprehensive comparison of the efficacy of relevant study identification between human researchers and ChatGPT has not been conducted.OBJECTIVE: This study aims to compare the efficacy of ChatGPT and human researchers in identifying relevant studies on medication adherence improvement using mobile health interventions in patients with ischemic stroke during systematic reviews.METHODS: This study used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Four electronic databases, including CINAHL Plus with Full Text, Web of Science, PubMed, and MEDLINE, were searched to identify articles published from inception until 2023 using search terms based on MeSH (Medical Subject Headings) terms generated by human researchers versus ChatGPT. The authors independently screened the titles, abstracts, and full text of the studies identified through separate searches conducted by human researchers and ChatGPT. The comparison encompassed several aspects, including the ability to retrieve relevant studies, accuracy, efficiency, limitations, and challenges associated with each method.RESULTS: A total of 6 articles identified through search terms generated by human researchers were included in the final analysis, of which 4 (67%) reported improvements in medication adherence after the intervention. However, 33% (2/6) of the included studies did not clearly state whether medication adherence improved after the intervention. A total of 10 studies were included based on search terms generated by ChatGPT, of which 6 (60%) overlapped with studies identified by human researchers. Regarding the impact of mobile health interventions on medication adherence, most included studies (8/10, 80%) based on search terms generated by ChatGPT reported improvements in medication adherence after the intervention. However, 20% (2/10) of the studies did not clearly state whether medication adherence improved after the intervention. The precision in accurately identifying relevant studies was higher in human researchers (0.86) than in ChatGPT (0.77). This is consistent with the percentage of relevance, where human researchers (9.8%) demonstrated a higher percentage of relevance than ChatGPT (3%). However, when considering the time required for both humans and ChatGPT to identify relevant studies, ChatGPT substantially outperformed human researchers as it took less time to identify relevant studies.CONCLUSIONS: Our comparative analysis highlighted the strengths and limitations of both approaches. Ultimately, the choice between human researchers and ChatGPT depends on the specific requirements and objectives of each review, but the collaborative synergy of both approaches holds the potential to advance evidence-based research and decision-making in the health care field.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38710069/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38710069</a> | DOI:<a href=https://doi.org/10.2196/51526>10.2196/51526</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38710069</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Suebsarn Ruksakulpiwat</dc:creator>
<dc:creator>Lalipat Phianhasin</dc:creator>
<dc:creator>Chitchanok Benjasirisan</dc:creator>
<dc:creator>Kedong Ding</dc:creator>
<dc:creator>Anuoluwapo Ajibade</dc:creator>
<dc:creator>Ayanesh Kumar</dc:creator>
<dc:creator>Cassie Stewart</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>JMIR mHealth and uHealth</dc:source>
<dc:title>Assessing the Efficacy of ChatGPT Versus Human Researchers in Identifying Relevant Studies on mHealth Interventions for Improving Medication Adherence in Patients With Ischemic Stroke When Conducting Systematic Reviews: Comparative Analysis</dc:title>
<dc:identifier>pmid:38710069</dc:identifier>
<dc:identifier>doi:10.2196/51526</dc:identifier>
</item>
<item>
<title>Noncontrast CT Selected Thrombectomy vs Medical Management for Late-Window Anterior Large Vessel Occlusion</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38709999/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>BACKGROUND AND OBJECTIVES: There is uncertainty whether patients with large vessel occlusion (LVO) presenting in the late 6-hour to 24-hour time window can be selected for endovascular therapy (EVT) by noncontrast CT (NCCT) and CT angiography (CTA) for LVO detection. We evaluated the clinical outcomes of patients selected for EVT by NCCT compared with those medically managed in the extended time window.</description>
<content:encoded><![CDATA[<div>Neurology. 2024 May 28;102(10):e209324. doi: 10.1212/WNL.0000000000209324. Epub 2024 May 6.ABSTRACTBACKGROUND AND OBJECTIVES: There is uncertainty whether patients with large vessel occlusion (LVO) presenting in the late 6-hour to 24-hour time window can be selected for endovascular therapy (EVT) by noncontrast CT (NCCT) and CT angiography (CTA) for LVO detection. We evaluated the clinical outcomes of patients selected for EVT by NCCT compared with those medically managed in the extended time window.METHODS: This multinational cohort study was conducted at 66 sites across 10 countries. Consecutive patients with proximal anterior LVO stroke selected for EVT by NCCT or medically managed and presenting within 6-24 hours of time last seen well (TSLW) from January 2014 to May 2022 were included. The primary end point was the 90-day ordinal shift in the modified Rankin Scale (mRS) score. Inverse probability treatment weighting (IPTW) and multivariable methods were used.RESULTS: Of 5,098 patients screened, 839 patients were included, with a median (interquartile range) age of 75 (64-83) years; 455 (54.2%) were women. There were 616 patients selected to undergo EVT by NCCT (73.4%) and 223 (26.6%) who were medically managed. In IPTW analyses, there was a more favorable 90-day ordinal mRS shift in patients selected by NCCT to EVT vs those who were medically managed (odds ratio [OR] 1.99, 95% CI 1.53-2.59; p < 0.001). There were higher rates of 90-day functional independence (mRS 0-2) in the EVT group (40.1% vs 18.4%, OR 3.31, 95% CI 2.11-5.20; p < 0.001). sICH was nonsignificantly higher in the EVT group (8.5% vs 1.4%, OR 3.77, 95% CI 0.72-19.7, p = 0.12). Mortality at 90 days was lower in the EVT vs MM group (23.9% vs 32.3%, OR 0.61, 95% CI 0.45-0.83, p = 0.002).DISCUSSION: In patients with proximal anterior LVO in the extended time window, there was a lower rate of disability and mortality in patients selected with NCCT and CTA to EVT compared with those who were medically managed. These findings support the use of NCCT as a simpler and more inclusive approach to patient selection in the extended window.TRIAL REGISTRATION INFORMATION: This study was registered at ClinicalTrials.gov under NCT04096248.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with proximal anterior circulation occlusion presenting with ischemic stroke from 6 to 24 hours, compared with medical management, those undergoing thrombectomy based on NCCT have reduced disability and mortality at 90 days.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709999/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38709999</a> | DOI:<a href=https://doi.org/10.1212/WNL.0000000000209324>10.1212/WNL.0000000000209324</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38709999</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Thanh N Nguyen</dc:creator>
<dc:creator>Raul G Nogueira</dc:creator>
<dc:creator>Muhammad M Qureshi</dc:creator>
<dc:creator>Simon Nagel</dc:creator>
<dc:creator>Jean Raymond</dc:creator>
<dc:creator>Mohamad Abdalkader</dc:creator>
<dc:creator>Jelle Demeestere</dc:creator>
<dc:creator>João Pedro Marto</dc:creator>
<dc:creator>Sunil A Sheth</dc:creator>
<dc:creator>Volker Puetz</dc:creator>
<dc:creator>Anne Dusart</dc:creator>
<dc:creator>Patrik Michel</dc:creator>
<dc:creator>Marc Ribo</dc:creator>
<dc:creator>Osama O Zaidat</dc:creator>
<dc:creator>James E Siegler</dc:creator>
<dc:creator>Diogo C Haussen</dc:creator>
<dc:creator>Daniel Strbian</dc:creator>
<dc:creator>Hilde Henon</dc:creator>
<dc:creator>Mahmoud H Mohammaden</dc:creator>
<dc:creator>Markus A Möhlenbruch</dc:creator>
<dc:creator>Marta Olive-Gadea</dc:creator>
<dc:creator>Ajit S Puri</dc:creator>
<dc:creator>Simon Winzer</dc:creator>
<dc:creator>Johannes Kaesmacher</dc:creator>
<dc:creator>Piers Klein</dc:creator>
<dc:creator>Liisa Tomppo</dc:creator>
<dc:creator>Francois Caparros</dc:creator>
<dc:creator>João Nuno Ramos</dc:creator>
<dc:creator>Mouhammad A Jumaa</dc:creator>
<dc:creator>Syed F Zaidi</dc:creator>
<dc:creator>Nicolas Martinez-Majander</dc:creator>
<dc:creator>Stefania Nannoni</dc:creator>
<dc:creator>Lieselotte Vandewalle</dc:creator>
<dc:creator>Flavio Bellante</dc:creator>
<dc:creator>Mudassir Farooqui</dc:creator>
<dc:creator>Sergio Salazar-Marioni</dc:creator>
<dc:creator>Pekka Virtanen</dc:creator>
<dc:creator>Daniel P O Kaiser</dc:creator>
<dc:creator>Anke Wouters</dc:creator>
<dc:creator>Rita Ventura</dc:creator>
<dc:creator>Jessica Jesser</dc:creator>
<dc:creator>Adnan Mujanovic</dc:creator>
<dc:creator>Liqi Shu</dc:creator>
<dc:creator>Alicia C Castonguay</dc:creator>
<dc:creator>Zain Mansoor</dc:creator>
<dc:creator>Zhongming Qiu</dc:creator>
<dc:creator>Hesham E Masoud</dc:creator>
<dc:creator>Manuel Requena</dc:creator>
<dc:creator>Erno Peltola</dc:creator>
<dc:creator>Wei Hu</dc:creator>
<dc:creator>Eugene Lin</dc:creator>
<dc:creator>Kanta Tanaka</dc:creator>
<dc:creator>Charlotte Cordonnier</dc:creator>
<dc:creator>Daniel Roy</dc:creator>
<dc:creator>Shadi Yaghi</dc:creator>
<dc:creator>Davide Strambo</dc:creator>
<dc:creator>Hiroshi Yamagami</dc:creator>
<dc:creator>Urs Fischer</dc:creator>
<dc:creator>Tudor G Jovin</dc:creator>
<dc:creator>Robin Lemmens</dc:creator>
<dc:creator>Peter A Ringleb</dc:creator>
<dc:creator>Santiago Ortega-Gutierrez</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Neurology</dc:source>
<dc:title>Noncontrast CT Selected Thrombectomy vs Medical Management for Late-Window Anterior Large Vessel Occlusion</dc:title>
<dc:identifier>pmid:38709999</dc:identifier>
<dc:identifier>doi:10.1212/WNL.0000000000209324</dc:identifier>
</item>
<item>
<title>Study protocol: Early neurological deterioration in patients with minor stroke, frequency, predictors, and outcomes in Vietnam single-centre study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38709783/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Early neurological deterioration (END) is progressive neurological deterioration with an increase in NIHSS score of 2 points or more in the first 72 hours from the onset of acute ischemic stroke. END increases the risk of poor clinical outcomes at day 90 of ischemic stroke. We will study the frequency, predictors, and outcomes of patients with END in a case-control study at a comprehensive stroke centre in Vietnam. of the design is a descriptive observational study, longitudinal follow-up of...</description>
<content:encoded><![CDATA[<div>PLoS One. 2024 May 6;19(5):e0302822. doi: 10.1371/journal.pone.0302822. eCollection 2024.ABSTRACTEarly neurological deterioration (END) is progressive neurological deterioration with an increase in NIHSS score of 2 points or more in the first 72 hours from the onset of acute ischemic stroke. END increases the risk of poor clinical outcomes at day 90 of ischemic stroke. We will study the frequency, predictors, and outcomes of patients with END in a case-control study at a comprehensive stroke centre in Vietnam. of the design is a descriptive observational study, longitudinal follow-up of patients with minor stroke hospitalized at the Stroke Center of Bach Mai Hospital from December 1, 2023, to December 1, 2024. Minor stroke patients characterized by NIHSS score ≤ 5 hospitalized within 24 hours of symptom onset will be recruited. The estimated END rate is about 30%, relative accuracy ε = 0.11, 95% reliability, expected 5% of patients lost data or follow-up, and an estimated sample size of 779 patients. This study will help determine the END rate in patients with minor stroke and related factors, thereby building a prognostic model for END. Our study determined the END rate in patients with minor stroke in Vietnam and also proposed risk factors for minor stroke management and treatment.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709783/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38709783</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11073673/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11073673</a> | DOI:<a href=https://doi.org/10.1371/journal.pone.0302822>10.1371/journal.pone.0302822</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38709783</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Dung Tien Nguyen</dc:creator>
<dc:creator>Ton Duy Mai</dc:creator>
<dc:creator>Phuong Viet Dao</dc:creator>
<dc:creator>Hung Tran Ha</dc:creator>
<dc:creator>Anh Tuan Le</dc:creator>
<dc:creator>Tuyet Trinh Thi Nguyen</dc:creator>
<dc:creator>Trung Xuan Vuong</dc:creator>
<dc:creator>Minh Cong Tran</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>PloS one</dc:source>
<dc:title>Study protocol: Early neurological deterioration in patients with minor stroke, frequency, predictors, and outcomes in Vietnam single-centre study</dc:title>
<dc:identifier>pmid:38709783</dc:identifier>
<dc:identifier>pmc:PMC11073673</dc:identifier>
<dc:identifier>doi:10.1371/journal.pone.0302822</dc:identifier>
</item>
<item>
<title>Astrocytic Slc4a4 regulates blood-brain barrier integrity in healthy and stroke brains via a CCL2-CCR2 pathway and NO dysregulation</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38709635/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Astrocytes play vital roles in blood-brain barrier (BBB) maintenance, yet how they support BBB integrity under normal or pathological conditions remains poorly defined. Recent evidence suggests that ion homeostasis is a cellular mechanism important for BBB integrity. In the current study, we investigated the function of an astrocyte-specific pH regulator, Slc4a4, in BBB maintenance and repair. We show that astrocytic Slc4a4 is required for normal astrocyte morphological complexity and BBB...</description>
<content:encoded><![CDATA[<div>Cell Rep. 2024 May 5;43(5):114193. doi: 10.1016/j.celrep.2024.114193. Online ahead of print.ABSTRACTAstrocytes play vital roles in blood-brain barrier (BBB) maintenance, yet how they support BBB integrity under normal or pathological conditions remains poorly defined. Recent evidence suggests that ion homeostasis is a cellular mechanism important for BBB integrity. In the current study, we investigated the function of an astrocyte-specific pH regulator, Slc4a4, in BBB maintenance and repair. We show that astrocytic Slc4a4 is required for normal astrocyte morphological complexity and BBB function. Multi-omics analyses identified increased astrocytic secretion of CCL2 coupled with dysregulated arginine-NO metabolism after Slc4a4 deletion. Using a model of ischemic stroke, we found that loss of Slc4a4 exacerbates BBB disruption, which was rescued by pharmacological or genetic inhibition of the CCL2-CCR2 pathway in vivo. Together, our study identifies the astrocytic Slc4a4-CCL2 and endothelial CCR2 axis as a mechanism controlling BBB integrity and repair, while providing insights for a therapeutic approach against BBB-related CNS disorders.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709635/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38709635</a> | DOI:<a href=https://doi.org/10.1016/j.celrep.2024.114193>10.1016/j.celrep.2024.114193</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38709635</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Qi Ye</dc:creator>
<dc:creator>Juyeon Jo</dc:creator>
<dc:creator>Chih-Yen Wang</dc:creator>
<dc:creator>Heavin Oh</dc:creator>
<dc:creator>Jiangshan Zhan</dc:creator>
<dc:creator>Tiffany J Choy</dc:creator>
<dc:creator>Kyoung In Kim</dc:creator>
<dc:creator>Angelo D'Alessandro</dc:creator>
<dc:creator>Yana K Reshetnyak</dc:creator>
<dc:creator>Sung Yun Jung</dc:creator>
<dc:creator>Zheng Chen</dc:creator>
<dc:creator>Sean P Marrelli</dc:creator>
<dc:creator>Hyun Kyoung Lee</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Cell reports</dc:source>
<dc:title>Astrocytic Slc4a4 regulates blood-brain barrier integrity in healthy and stroke brains via a CCL2-CCR2 pathway and NO dysregulation</dc:title>
<dc:identifier>pmid:38709635</dc:identifier>
<dc:identifier>doi:10.1016/j.celrep.2024.114193</dc:identifier>
</item>
<item>
<title>Persistent intracranial steno-occlusion from calcified embolism: a treatment challenge</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38709382/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Calcified cerebral embolism is a rare cause of stroke, but it is largely underreported and both acute phase and secondary preventive treatment have to be defined.</description>
<content:encoded><![CDATA[<div>Neurol Sci. 2024 May 6. doi: 10.1007/s10072-024-07575-9. Online ahead of print.ABSTRACTINTRODUCTION: Calcified arterial cerebral embolism is a rare occurrence among large and medium vessel occlusions causing ischemic stroke and its diagnosis and treatment is a challenge. The sources of calcified embolism might be a calcific atheroma from the aortic arch and carotid artery, but also heart valve disease has been reported in the literature. Calcified embolism is frequently simultaneous on multiple vascular territories. The prognosis of patients is usually poor, including patients treated by using endovascular thrombectomy (EVT) and this diagnosis could be easily missed in the acute phase. In addition, the optimal secondary prevention has not been yet fully stated.METHODS: We are presenting two cases of acute stroke due to calcified embolism in the middle cerebral artery (MCA) coming from a complicated carotid atheroma, non-stenosing in the first case (a 49 years old man) and stenosing in the second case (a 71 years old man) without clinical indications to intravenous thrombolysis and/or EVT, extensively investigated in the acute phase and followed-up for over 12 months with a favorable clinical course and the persisting steno-occlusion in the involved MCA. In both cases, antiplatelet treatment and targeting of vascular risk factors were done without recurrences in the follow-up period.DISCUSSION: Cerebral calcified embolism has been reported in 5.9% of cases of acute ischemic stroke in a single center series and only in 1.2% of a large retrospective cohort of EVT-treated patients. In both series the prognosis was poor and only one third of EVT-treated patients had functional independence at 3-months follow-up. The natural history of these subtype of ischemic stroke is relatively poorly understood and both etiological diagnosis and treatment have not yet defined. It is possible that some cases might be underdiagnosed and underreported.CONCLUSIONS: Calcified cerebral embolism is a rare cause of stroke, but it is largely underreported and both acute phase and secondary preventive treatment have to be defined.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709382/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38709382</a> | DOI:<a href=https://doi.org/10.1007/s10072-024-07575-9>10.1007/s10072-024-07575-9</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38709382</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Marialuisa Zedde</dc:creator>
<dc:creator>Ilaria Grisendi</dc:creator>
<dc:creator>Federica Assenza</dc:creator>
<dc:creator>Manuela Napoli</dc:creator>
<dc:creator>Claudio Moratti</dc:creator>
<dc:creator>Giovanna Di Cecco</dc:creator>
<dc:creator>Claudio Pavone</dc:creator>
<dc:creator>Lara Bonacini</dc:creator>
<dc:creator>Serena D'Aniello</dc:creator>
<dc:creator>Franco Valzania</dc:creator>
<dc:creator>Rosario Pascarella</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</dc:source>
<dc:title>Persistent intracranial steno-occlusion from calcified embolism: a treatment challenge</dc:title>
<dc:identifier>pmid:38709382</dc:identifier>
<dc:identifier>doi:10.1007/s10072-024-07575-9</dc:identifier>
</item>
<item>
<title>Prevalence and Prognostic Impact of Stroke in a National Cohort of Infective Endocarditis</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708722/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: One fifth of patients with IE have concomitant stroke. Stroke is associated with mortality.</description>
<content:encoded><![CDATA[<div>Int J Stroke. 2024 May 6:17474930241255560. doi: 10.1177/17474930241255560. Online ahead of print.ABSTRACTBACKGROUND: Stroke is a common complication of infective endocarditis (IE). Our aim was to describe the prevalence and prognostic impact of stroke in a national prospective cohort of IE.METHODS: Consecutive inclusion at 46 Spanish hospitals between 2008 and 2021.RESULTS: Out of 5667 IE cases, 1125 had acute stroke (19.8%): 811 ischemic strokes (618 cardioembolic strokes, 193 cardioembolic strokes with hemorrhagic transformation, 4 transient ischemic attacks, 3 lacunar infarctions), 125 intracranial hemorrhages, and 29 other neurological complications (cerebral abscesses, encephalitis, meningitis, seizures). Compared to patients without stroke, those with stroke had a similar mean age (69 years) but were more frequently female (68.2% vs. 63.7%, p=0.04) and had a higher incidence of intracardiac complications (35% vs 30%, p=0.01), surgical indication (69.9% vs 65.9%, p=0.001), in-hospital mortality (40.9% vs. 22.0%, p<0.001), and one-year mortality (46.2% vs 27.9%, p<0.001). The following variables were independently associated with stroke: mitral location (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.34-1.8, p<0.001), vascular phenomenon (OR 2.9, 95% CI 2.4-3.6, p=0.0001), acute renal failure (OR 1.2, 95% CI 1.0-1.4, p=0.021), septic shock (OR 1.3, CI 1.1-1.6, p=0.007), sepsis (OR 1.3, CI 1.1-1.6, p=0.005), surgery indicated but not performed (OR 1.4, 95% CI 1.2-1.7, p<0.001), community-acquired IE (OR 1.2, 95% CI 1-1.4, p=0.017), and peripheral embolization (OR 1.6, CI 1.4-1.9, p <0.001). Stroke was an independent predictor of in-hospital (OR 2.1, 95% CI: 1.78-2.51, p<0.001) and one-year mortality (hazard ratio 1.9, 95% CI 1.6-2.5).CONCLUSIONS: One fifth of patients with IE have concomitant stroke. Stroke is associated with mortality.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708722/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708722</a> | DOI:<a href=https://doi.org/10.1177/17474930241255560>10.1177/17474930241255560</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708722</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sara Álvarez Zaballos</dc:creator>
<dc:creator>Pilar Vazquez Alen</dc:creator>
<dc:creator>Patricia Muñoz</dc:creator>
<dc:creator>Arístides de Alarcón</dc:creator>
<dc:creator>Encarnación Gutiérrez-Carretero</dc:creator>
<dc:creator>Ana Álvarez-Uría</dc:creator>
<dc:creator>Mª Carmen Fariñas</dc:creator>
<dc:creator>Raquel Rodríguez-García</dc:creator>
<dc:creator>Miguel Ángel Goenaga</dc:creator>
<dc:creator>Guillermo Cuervo</dc:creator>
<dc:creator>Antonio Plata-Ciezar</dc:creator>
<dc:creator>Carmen Hidalgo-Tenorio</dc:creator>
<dc:creator>Gonzalo Aldamiz-Echevarría</dc:creator>
<dc:creator>Manuel Martínez-Sellés</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>International journal of stroke : official journal of the International Stroke Society</dc:source>
<dc:title>Prevalence and Prognostic Impact of Stroke in a National Cohort of Infective Endocarditis</dc:title>
<dc:identifier>pmid:38708722</dc:identifier>
<dc:identifier>doi:10.1177/17474930241255560</dc:identifier>
</item>
<item>
<title>Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708609/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Patients with advanced CKD undergoing Impella-assisted high-risk PCI tend to have higher baseline comorbidities, severe coronary calcification, and higher atherectomy usage, yet CKD was not associated with a higher rate of immediate PCI-related complications. However, 90-day major adverse cardiovascular and cerebrovascular events and 1-year mortality were significantly higher among patients with eGFR<30 mL/min per 1.73 m² or on dialysis. Future studies of strategies to improve...</description>
<content:encoded><![CDATA[<div>Circ Cardiovasc Interv. 2024 May 6:e013503. doi: 10.1161/CIRCINTERVENTIONS.123.013503. Online ahead of print.ABSTRACTBACKGROUND: Prior studies have found that patients with chronic kidney disease (CKD) have worse outcomes following percutaneous coronary intervention (PCI). There are no data about patients with advanced CKD undergoing Impella-supported high-risk PCI. We, therefore, aimed to evaluate angiographic characteristics and clinical outcomes in patients with CKD who received Impella-supported high-risk PCI as part of the catheter-based ventricular assist device PROTECT III study (A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump [IABP] in Patients Undergoing Non Emergent High Risk PCI).METHODS: Patients enrolled in the PROTECT III study were analyzed according to their baseline estimated glomerular filtration rate (eGFR). The primary outcome was 90-day major adverse cardiovascular and cerebrovascular events (the composite of all-cause death, myocardial infarction, stroke/transient ischemic attack, and repeat revascularization).RESULTS: Of 1237 enrolled patients, 1052 patients with complete eGFR baseline assessment were evaluated: 586 with eGFR ≥60 mL/min per 1.73 m2, 190 with eGFR ≥45 to <60, 105 with eGFR ≥30 to <45, and 171 with eGFR <30 or on dialysis. Patients with lower eGFR (all groups with eGFR <60) were more frequently females and had a higher prevalence of hypertension, diabetes, anemia, and peripheral artery disease. The baseline Synergy Between PCI With Taxus and Cardiac Surgery score was similar between groups (28.2±12.6 for all groups). Patients with lower eGFR were more likely to have severe coronary calcifications and higher usage of atherectomy. There were no differences in individual PCI-related coronary complications between groups, but the rates of overall PCI complications were less frequent among patients with lower eGFR. Major adverse cardiovascular and cerebrovascular events at 90 days and 1-year mortality were significantly higher among patients with eGFR <30 mL/min per 1.73 m2 or on dialysis.CONCLUSIONS: Patients with advanced CKD undergoing Impella-assisted high-risk PCI tend to have higher baseline comorbidities, severe coronary calcification, and higher atherectomy usage, yet CKD was not associated with a higher rate of immediate PCI-related complications. However, 90-day major adverse cardiovascular and cerebrovascular events and 1-year mortality were significantly higher among patients with eGFR<30 mL/min per 1.73 m2 or on dialysis. Future studies of strategies to improve intermediate and long-term outcomes of these high-risk patients are warranted.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04136392.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708609/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708609</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.123.013503>10.1161/CIRCINTERVENTIONS.123.013503</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708609</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Aditya S Bharadwaj</dc:creator>
<dc:creator>Arsalan Abu-Much</dc:creator>
<dc:creator>Aneel S Maini</dc:creator>
<dc:creator>Zhipeng Zhou</dc:creator>
<dc:creator>Yanru Li</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Cindy L Grines</dc:creator>
<dc:creator>Suzanne J Baron</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study</dc:title>
<dc:identifier>pmid:38708609</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.123.013503</dc:identifier>
</item>
<item>
<title>Top 4 Research Studies of the month for Italian Primary Care Physicians: April 2024.</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708536/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>This monthly article provides a collection of summaries of the most relevant studies identified as POEMs (patient-oriented evidence that matters) for Italian primary care physicians. 1) In children and adults with acute conjunctivitis, antibiotic drops increase the likelihood that a patient will experience clinical recovery. Damage appears to be minimal for all agents other than fusidic acid (therefore, fusidic acid should be avoided). Since most patients improve without antibiotics, the benefit...</description>
<content:encoded><![CDATA[<div>Recenti Prog Med. 2024 May;115(5):243-247. doi: 10.1701/4262.42404.ABSTRACTThis monthly article provides a collection of summaries of the most relevant studies identified as POEMs (patient-oriented evidence that matters) for Italian primary care physicians. 1) In children and adults with acute conjunctivitis, antibiotic drops increase the likelihood that a patient will experience clinical recovery. Damage appears to be minimal for all agents other than fusidic acid (therefore, fusidic acid should be avoided). Since most patients improve without antibiotics, the benefit is modest, and there is a risk of antibiotic resistance, we would avoid them for patients with milder symptoms, especially immunocompetent adults. 2) A high quality randomized controlled trial was recently conducted on more than 4000 adult patients with recurrent episodes of subclinical atrial fibrillation. Trialists found that there was approximately 1 fewer ischemic stroke and 1 more major bleed for every 250 persons treated with apixaban instead of aspirin, but in people treated with apixaban major bleeding was also significantly more likely. This seems like a decision that requires an informed patient and shared decision-making. 3) In an intriguing but somewhat limited network meta-analysis, probiotics were equally or more effective than treatment with any antidepressant except escitalopram. Given the low advantage of standard treatments over placebo, probiotic treatment might be offered to patients who are reluctant to use antidepressants. 4) A recent meta-analysis showed that amyloid-targeting monoclonal antibodies do not provide any clinical meaningful benefits for patients with Alzheimer disease. Instead, they are associated with concerning risks of harm, most notably cerebral hemorrhage identified on imaging studies. The balance of risk versus benefit demonstrated thus far doesn't justify the use of these costly (over US$ 20,000 annually) drugs.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708536/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708536</a> | DOI:<a href=https://doi.org/10.1701/4262.42404>10.1701/4262.42404</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708536</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter K Kurotschka</dc:creator>
<dc:creator>Alice Serafini</dc:creator>
<dc:creator>Allen F Shaughnessy</dc:creator>
<dc:creator>David Slawson</dc:creator>
<dc:creator>Mark H Ebell</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Recenti progressi in medicina</dc:source>
<dc:title>Top 4 Research Studies of the month for Italian Primary Care Physicians: April 2024.</dc:title>
<dc:identifier>pmid:38708536</dc:identifier>
<dc:identifier>doi:10.1701/4262.42404</dc:identifier>
</item>
<item>
<title>Circulating HMGB1 in acute ischemic stroke and its association with post-stroke cognitive impairment</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708343/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Circulating HMGB1 concentrations quantified within the first 24 hours following acute cerebral infarction are significantly and independently correlated with the likelihood of developing cognitive dysfunction at the 3-month follow-up, even after accounting for potential confounding factors. HMGB1 may be a novel biomarker to identify patients likely to develop post-stroke cognitive impairment for targeted preventive interventions.</description>
<content:encoded><![CDATA[<div>PeerJ. 2024 Apr 30;12:e17309. doi: 10.7717/peerj.17309. eCollection 2024.ABSTRACTBACKGROUND: Ischemic stroke frequently leads to a condition known as post-stroke cognitive impairment (PSCI). Timely recognition of individuals susceptible to developing PSCI could facilitate the implementation of personalized strategies to mitigate cognitive deterioration. High mobility group box 1 (HMGB1) is a protein released by ischemic neurons and implicated in inflammation after stroke. Circulating levels of HMGB1 could potentially serve as a prognostic indicator for the onset of cognitive impairment following ischemic stroke.OBJECTIVE: To investigate the predictive value of circulating HMGB1 concentrations in the acute phase of ischemic stroke for the development of cognitive dysfunction at the 3-month follow-up.METHODS: A total of 192 individuals experiencing their initial episode of acute cerebral infarction were prospectively recruited for this longitudinal investigation. Concentrations of circulating HMGB1 were quantified using an enzyme-linked immunosorbent assay (ELISA) technique within the first 24 hours following hospital admission. Patients underwent neurological evaluation including NIHSS scoring. Neuropsychological evaluation was conducted at the 3-month follow-up after the cerebrovascular event, employing the Montreal Cognitive Assessment (MoCA) as the primary tool for assessing cognitive performance. Multivariable logistic regression models were employed to investigate the relationship between circulating HMGB1 concentrations and cognitive dysfunction following stroke, which was operationalized as a MoCA score below 26, while controlling for potential confounders including demographic characteristics, stroke severity, vascular risk factors, and laboratory parameters.RESULTS: Of 192 patients, 84 (44%) developed PSCI. Circulating HMGB1 concentrations were significantly elevated in individuals who developed cognitive dysfunction following stroke compared to those who maintained cognitive integrity (8.4 ± 1.2 ng/mL vs 4.6 ± 0.5 ng/mL, respectively; p < 0.001). The prevalence of PSCI showed a dose-dependent increase with higher HMGB1 quartiles. After controlling for potential confounders such as demographic factors (age, gender, and education), stroke severity, vascular risk factors, and laboratory parameters in a multivariable logistic regression model, circulating HMGB1 concentrations emerged as a significant independent predictor of cognitive dysfunction following stroke (regression coefficient = 0.236, p < 0.001).CONCLUSION: Circulating HMGB1 concentrations quantified within the first 24 hours following acute cerebral infarction are significantly and independently correlated with the likelihood of developing cognitive dysfunction at the 3-month follow-up, even after accounting for potential confounding factors. HMGB1 may be a novel biomarker to identify patients likely to develop post-stroke cognitive impairment for targeted preventive interventions.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708343/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708343</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11067911/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11067911</a> | DOI:<a href=https://doi.org/10.7717/peerj.17309>10.7717/peerj.17309</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708343</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhenbao Liu</dc:creator>
<dc:creator>Weixia Yang</dc:creator>
<dc:creator>Jianxin Chen</dc:creator>
<dc:creator>Qian Wang</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>PeerJ</dc:source>
<dc:title>Circulating HMGB1 in acute ischemic stroke and its association with post-stroke cognitive impairment</dc:title>
<dc:identifier>pmid:38708343</dc:identifier>
<dc:identifier>pmc:PMC11067911</dc:identifier>
<dc:identifier>doi:10.7717/peerj.17309</dc:identifier>
</item>
<item>
<title>Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708004/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Tenecteplase significantly reduced DNT and DPT. It was associated with early neurological function improvement (at 24 h), without compromising safety compared to alteplase. The findings support tenecteplase's application in AIS.</description>
<content:encoded><![CDATA[<div>Front Neurol. 2024 Apr 19;15:1386386. doi: 10.3389/fneur.2024.1386386. eCollection 2024.ABSTRACTBACKGROUND: This retrospective observational cohort study aimed to evaluate whether tenecteplase's use for acute ischemic stroke (AIS) has time management advantages and clinical benefits.METHODS: 144 AIS patients treated with alteplase and 120 with tenecteplase were included. We compared baseline clinical characteristics, key reperfusion therapy time indices [onset-to-treatment time (OTT), door-to-needle time (DNT), and door-to-puncture time (DPT)] and clinical outcomes (24-h post-thrombolysis NIHSS improvement, and intracranial hemorrhage incidence) between the groups using univariate analysis. We assessed hospital stay durations and used binary logistic regression to examine tenecteplase's association with DNT and DPT target times, NIHSS improvement, and intracranial hemorrhage.RESULTS: Baseline characteristics showed no significant differences except hyperlipidemia and atrial fibrillation. OTT (133 vs. 163.72, p = 0.001), DNT (36.5 vs. 50, p < 0.001) and DPT (117 vs. 193, p = 0.002) were significantly faster in the tenecteplase group. The rates of DNT ≤ 45 min (65.83% vs. 40.44%, p < 0.001) and DPT ≤ 120 min (59.09% vs. 13.79%, p = 0.001) were significantly higher in the tenecteplase group. Tenecteplase was an independent predictor of achieving target DNT (OR 2.951, 95% CI 1.732-5.030; p < 0.001) and DPT (OR 7.867, 95% CI 1.290-47.991; p = 0.025). Clinically, the proportion NIHSS improvement 24 h post-thrombolysis was higher in the tenecteplase group (64.17% vs. 50%, p = 0.024). No significant differences were observed in symptomatic intracranial hemorrhage (sICH) or any intracranial hemorrhage (ICH). Patients receiving tenecteplase had shorter hospital stays (6 vs. 8 days, p < 0.001). Tenecteplase was an independent predictor of NIHSS improvement at 24 h (OR 1.715, 95% CI 1.011-2.908; p = 0.045). There was no significant association between thrombolytic choice and sICH or any ICH.CONCLUSION: Tenecteplase significantly reduced DNT and DPT. It was associated with early neurological function improvement (at 24 h), without compromising safety compared to alteplase. The findings support tenecteplase's application in AIS.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708004/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708004</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066233/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066233</a> | DOI:<a href=https://doi.org/10.3389/fneur.2024.1386386>10.3389/fneur.2024.1386386</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708004</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yu Yao</dc:creator>
<dc:creator>Yuefei Wu</dc:creator>
<dc:creator>Xiaoqin Zhang</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Lingling Cai</dc:creator>
<dc:creator>Yisha Ying</dc:creator>
<dc:creator>Jianhong Yang</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Frontiers in neurology</dc:source>
<dc:title>Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis</dc:title>
<dc:identifier>pmid:38708004</dc:identifier>
<dc:identifier>pmc:PMC11066233</dc:identifier>
<dc:identifier>doi:10.3389/fneur.2024.1386386</dc:identifier>
</item>
<item>
<title>A CT texture-based nomogram for predicting futile reperfusion in patients with intraparenchymal hyperdensity after endovascular thrombectomy for acute anterior circulation large vessel occlusion</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38708002/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: The nomogram enables clinicians to accurately predict FR specifically in patients with PTIH within half an hour after EVT and helps to formulate more appropriate treatment plans in the early post-EVT period.</description>
<content:encoded><![CDATA[<div>Front Neurol. 2024 Apr 19;15:1327585. doi: 10.3389/fneur.2024.1327585. eCollection 2024.ABSTRACTBACKGROUND: Post-thrombectomy intraparenchymal hyperdensity (PTIH) in patients with acute anterior circulation large vessel occlusion is a common CT sign associated with a higher incidence of futile reperfusion (FR). We aimed to develop a nomogram to predict FR specifically in patients with PTIH.METHODS: We retrospectively collected information on patients with acute ischemic stroke who underwent endovascular thrombectomy (EVT) at two stroke centers. A total of 398 patients with PTIH were included to develop and validate the nomogram, including 214 patients in the development cohort, 92 patients in the internal validation cohort and 92 patients in the external validation cohort. The nomogram was developed according to the independent predictors obtained from multivariate logistic regression analysis, including clinical factors and CT texture features extracted from hyperdense areas on CT images within half an hour after EVT. The performance of the nomogram was evaluated with integrated discrimination improvement (IDI), category-free net reclassification improvement (NRI), the area under the receiver operating characteristic curve (AUC-ROC), calibration plots, and decision curve analyses for discrimination, calibration ability, and clinical net benefits, respectively.RESULTS: Our nomogram was constructed based on three clinical factors (age, NIHSS score and ASPECT score) and two CT texture features (entropy and kurtosis), with AUC-ROC of 0.900, 0.897, and 0.870 in the development, internal validation, and external validation cohorts, respectively. NRI and IDI further validated the superior predictive ability of the nomogram compared to the clinical model. The calibration plot revealed good consistency between the predicted and the actual outcome. The decision curve indicated good positive net benefit and clinical validity of the nomogram.CONCLUSION: The nomogram enables clinicians to accurately predict FR specifically in patients with PTIH within half an hour after EVT and helps to formulate more appropriate treatment plans in the early post-EVT period.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708002/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38708002</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066250/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066250</a> | DOI:<a href=https://doi.org/10.3389/fneur.2024.1327585>10.3389/fneur.2024.1327585</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38708002</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Meijuan Dong</dc:creator>
<dc:creator>Chun Chen</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:creator>Kun An</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Frontiers in neurology</dc:source>
<dc:title>A CT texture-based nomogram for predicting futile reperfusion in patients with intraparenchymal hyperdensity after endovascular thrombectomy for acute anterior circulation large vessel occlusion</dc:title>
<dc:identifier>pmid:38708002</dc:identifier>
<dc:identifier>pmc:PMC11066250</dc:identifier>
<dc:identifier>doi:10.3389/fneur.2024.1327585</dc:identifier>
</item>
<item>
<title>Prophylactic zinc and therapeutic selenium administration in adult rats prevents long-term cognitive and behavioral sequelae by a transient ischemic attack</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38707461/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>The transient hypoxic-ischemic attack, also known as a minor stroke, can result in long-term neurological issues such as memory loss, depression, and anxiety due to an increase in nitrosative stress. The individual or combined administration of chronic prophylactic zinc and therapeutic selenium is known to reduce nitrosative stress in the first seven days post-reperfusion and, due to an antioxidant effect, prevent cell death. Besides, zinc or selenium, individually administered, also causes...</description>
<content:encoded><![CDATA[<div>Heliyon. 2024 Apr 25;10(9):e30017. doi: 10.1016/j.heliyon.2024.e30017. eCollection 2024 May 15.ABSTRACTThe transient hypoxic-ischemic attack, also known as a minor stroke, can result in long-term neurological issues such as memory loss, depression, and anxiety due to an increase in nitrosative stress. The individual or combined administration of chronic prophylactic zinc and therapeutic selenium is known to reduce nitrosative stress in the first seven days post-reperfusion and, due to an antioxidant effect, prevent cell death. Besides, zinc or selenium, individually administered, also causes antidepressant and anxiolytic effects. Therefore, this work evaluated whether combining zinc and selenium could prevent stroke-elicited cognition and behavior deficits after 30 days post-reperfusion. Accordingly, we assessed the expression of growth factors at 7 days post-reperfusion, a four-time course of memory (from 7 to 28 days post-learning test), and cell proliferation, depression, and anxiety-like behavior at 30 days post-reperfusion. Male Wistar rats with a weight between 190 and 240 g) were treated with chronic prophylactic zinc administration with a concentration of 0.2 mg/kg for 15 days before common carotid artery occlusion (10 min) and then with therapeutic selenium (6 μg/kg) for 7 days post-reperfusion. Compared with individual administrations, the administration combined of prophylactic zinc and therapeutic selenium decreased astrogliosis, increased growth factor expression, and improved cell proliferation and survival in two regions, the hippocampus, and cerebral cortex. These effects prevented memory loss, depression, and anxiety-like behaviors. In conclusion, these results demonstrate that the prophylactic zinc administration combined with therapeutic selenium can reduce the long-term sequelae caused by the transient ischemic attack. Significance statement. A minor stroke caused by a transient ischemic attack can result in psychomotor sequelae that affect not only the living conditions of patients and their families but also the economy. The incidence of these micro-events among young people has increased in the world. Nonetheless, there is no deep understanding of how this population group responds to regular treatments (Ekker and et al., 2018) [1]. On the basis that zinc and selenium have antioxidant, anti-inflammatory, and regenerative properties in stroke animal models, our work explored whether the chronic combined administration of prophylactic zinc and therapeutic selenium could prevent neurological sequelae in the long term in a stroke rat model of unilateral common carotid artery occlusion (CCAO) by 10-min. Our results showed that this combined treatment provided a long-term neuroprotective effect by decreasing astrogliosis, memory loss, anxiety, and depression-like behavior.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38707461/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38707461</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11068621/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11068621</a> | DOI:<a href=https://doi.org/10.1016/j.heliyon.2024.e30017>10.1016/j.heliyon.2024.e30017</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38707461</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Constantino Tomas-Sanchez</dc:creator>
<dc:creator>Victor Manuel Blanco-Alvarez</dc:creator>
<dc:creator>Juan Antonio Gonzalez-Barrios</dc:creator>
<dc:creator>Daniel Martinez-Fong</dc:creator>
<dc:creator>Guadalupe Soto-Rodriguez</dc:creator>
<dc:creator>Eduardo Brambila</dc:creator>
<dc:creator>Alejandro Gonzalez-Vazquez</dc:creator>
<dc:creator>Ana Karina Aguilar-Peralta</dc:creator>
<dc:creator>Daniel I Limón</dc:creator>
<dc:creator>Viridiana Vargas-Castro</dc:creator>
<dc:creator>Jorge Cebada</dc:creator>
<dc:creator>Victorino Alatriste-Bueno</dc:creator>
<dc:creator>Bertha Alicia Leon-Chavez</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Heliyon</dc:source>
<dc:title>Prophylactic zinc and therapeutic selenium administration in adult rats prevents long-term cognitive and behavioral sequelae by a transient ischemic attack</dc:title>
<dc:identifier>pmid:38707461</dc:identifier>
<dc:identifier>pmc:PMC11068621</dc:identifier>
<dc:identifier>doi:10.1016/j.heliyon.2024.e30017</dc:identifier>
</item>
<item>
<title>Sex differences in the correlation between white matter hyperintensity and 3-month outcome in acute stroke patients</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38707361/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: The risk of unfavorable outcomes increased proportionally with the enlargement of the WMH severity in females, suggesting the sex-specific value of the WMH severity in optimizing the risk stratification of stroke.</description>
<content:encoded><![CDATA[<div>Heliyon. 2024 Apr 25;10(9):e30190. doi: 10.1016/j.heliyon.2024.e30190. eCollection 2024 May 15.ABSTRACTBACKGROUND: The severity of white matter hyperintensities (WMH) has been shown to be an independent predictor of poor stroke outcome, but the effect of sex on this correlation has not been investigated further. Therefore, the purpose of our study was to assess whether there was a sex difference between the severity of WMH and poor stroke outcome.METHODS: This retrospective study included 449 patients with acute ischemic stroke (AIS) who received intravenous thrombolysis. WMH severity was graded based on the Fazekas scale. The association between WMH severity and stroke outcome was explored through multivariable regression analyses in men and women.RESULTS: Among women, when dividing WMH severity into tertiles, T3 (Fazekas scale >3) had a 5.334 times higher risk for unfavorable outcomes than T1 (Fazekas scale <2) (p-trend = 0.026) in the adjusted model. In addition, moderate-severe WMH (Fazekas scale 3-6) had a 3.391 (1.151-9.991) times higher risk than none-mild WMH (Fazekas scale 0-2) (p = 0.027).CONCLUSIONS: The risk of unfavorable outcomes increased proportionally with the enlargement of the WMH severity in females, suggesting the sex-specific value of the WMH severity in optimizing the risk stratification of stroke.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38707361/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38707361</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066628/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066628</a> | DOI:<a href=https://doi.org/10.1016/j.heliyon.2024.e30190>10.1016/j.heliyon.2024.e30190</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38707361</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Junli Ren</dc:creator>
<dc:creator>Xia Zhang</dc:creator>
<dc:creator>Haobo Xie</dc:creator>
<dc:creator>Xinbo Zhou</dc:creator>
<dc:creator>Jiahan Xu</dc:creator>
<dc:creator>Haojie Qiu</dc:creator>
<dc:creator>Jielin Zhou</dc:creator>
<dc:creator>Wei Xie</dc:creator>
<dc:creator>Siqi Chen</dc:creator>
<dc:creator>Xin Lu</dc:creator>
<dc:creator>Yichuan Fan</dc:creator>
<dc:creator>Dehao Yang</dc:creator>
<dc:creator>Guangyong Chen</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Heliyon</dc:source>
<dc:title>Sex differences in the correlation between white matter hyperintensity and 3-month outcome in acute stroke patients</dc:title>
<dc:identifier>pmid:38707361</dc:identifier>
<dc:identifier>pmc:PMC11066628</dc:identifier>
<dc:identifier>doi:10.1016/j.heliyon.2024.e30190</dc:identifier>
</item>
<item>
<title>Combined intravenous and intra-arterial thrombolysis in hyperacute cerebral ischemia without significant corresponding vascular occlusion/stenosis: A Preliminary investigation</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38707359/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: In patients with acute ischemic stroke with an onset time of ≤6 h and no major intracranial vessel occlusion, combining rt-PA intravenous thrombolysis with intra-arterial thrombolysis via a microcatheter might yield superior functional outcomes.</description>
<content:encoded><![CDATA[<div>Heliyon. 2024 Apr 22;10(9):e29998. doi: 10.1016/j.heliyon.2024.e29998. eCollection 2024 May 15.ABSTRACTOBJECTIVE: In this study, we assessed the efficacy and safety of various thrombolytic treatment protocols in patients with hyperacute cerebral infarction.METHODS: Patients diagnosed with acute ischemic stroke within 6 h of symptom onset and with brain computer tomography angiography confirming the absence of major vessel stenosis or occlusion were eligible for this study. The enrolled patients were subsequently randomized into two groups: all the groups received the standard intravenous thrombolysis treatment with rt-PA (0.9 mg/kg), and the experimental group underwent sequential intra-arterial thrombolysis treatment with alteplase (0.3 mg/kg, with a maximum dose of 22 mg), administered directly into the target vessel via a microcatheter. Both groups were closely monitored for changes in their National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin scale score, hemorrhage rate, all-cause mortality rate, and the rate of favorable outcomes at 90 ± 7 days.RESULTS: Ninety-four participants were enrolled in this study, with both the control and experimental groups initiating intravenous injection of rt-PA at a median time of 29 min. For the experimental group, the median time for arterial puncture was 123 min. Baseline data for both groups were similar (P > 0.05). Hemorrhagic transformation occurred in 24.47 % (23 patients), with a lower intracranial hemorrhage rate observed in the experimental group compared to the control group (15.2 % vs 33.3 %, P < 0.05). Asymptomatic hemorrhage rates were 8.7 % for the experimental group and 12.5 % for the control group, with no hemorrhage detected in other locations. Post-treatment median NIHSS scores were lower in the experimental group than in the control group (7 vs 9, P < 0.05), but short-term NIHSS scores were similar (P > 0.05). A higher proportion of patients in the experimental group achieved favorable outcomes compared to the control group (87.0 % vs 43.8 %, P < 0.05).CONCLUSION: In patients with acute ischemic stroke with an onset time of ≤6 h and no major intracranial vessel occlusion, combining rt-PA intravenous thrombolysis with intra-arterial thrombolysis via a microcatheter might yield superior functional outcomes.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38707359/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38707359</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066378/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066378</a> | DOI:<a href=https://doi.org/10.1016/j.heliyon.2024.e29998>10.1016/j.heliyon.2024.e29998</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38707359</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xinming Li</dc:creator>
<dc:creator>Yan Tan</dc:creator>
<dc:creator>Jinzhao Song</dc:creator>
<dc:creator>Hongying Lu</dc:creator>
<dc:creator>Yuan Bian</dc:creator>
<dc:creator>Wenqiang Cai</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Heliyon</dc:source>
<dc:title>Combined intravenous and intra-arterial thrombolysis in hyperacute cerebral ischemia without significant corresponding vascular occlusion/stenosis: A Preliminary investigation</dc:title>
<dc:identifier>pmid:38707359</dc:identifier>
<dc:identifier>pmc:PMC11066378</dc:identifier>
<dc:identifier>doi:10.1016/j.heliyon.2024.e29998</dc:identifier>
</item>
<item>
<title>Management Approaches and Patient Outcomes for Giant Pituitary Neuroendocrine Tumors Classified as Knosp Grade 3 and 4</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38707178/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Background Treatment of patients with a giant pituitary neuroendocrine tumor (GPitNET) is challenging. Here, we present the methods used for the clinical management of patients who underwent GPitNET resection mainly via endoscopic endonasal surgery along with multimodal support to avoid surgical complications, which can affect the outcomes. Methodology The medical records of 25 patients with a GPitNET who underwent endonasal endoscopic surgery were retrospectively reviewed. Complications were...</description>
<content:encoded><![CDATA[<div>Cureus. 2024 Apr 3;16(4):e57498. doi: 10.7759/cureus.57498. eCollection 2024 Apr.ABSTRACTBackground Treatment of patients with a giant pituitary neuroendocrine tumor (GPitNET) is challenging. Here, we present the methods used for the clinical management of patients who underwent GPitNET resection mainly via endoscopic endonasal surgery along with multimodal support to avoid surgical complications, which can affect the outcomes. Methodology The medical records of 25 patients with a GPitNET who underwent endonasal endoscopic surgery were retrospectively reviewed. Complications were analyzed and factors affecting the extent of resection were evaluated. Results Gross total resection was achieved in six (24%), near-total resection (>90%) in nine (36%), and partial resection in 10 (40%) patients. Multivariate analyses revealed that tumors invading the middle fossa had negative effects on the extent of resection (odds ratio = 0.092, p = 0.047). Postoperative vision improved or normalized in 16 (64%), remained stable in eight (32%), and worsened in one (4%), while a new hormonal deficit was noted in seven (28%) patients. Complications included permanent oculomotor nerve palsy in one (4%) and transient oculomotor palsy in one (4%), apoplexy of the residual tumor resulting in ischemic stroke in one (4%), postoperative cerebrospinal fluid leakage in one (4%), and permanent diabetes insipidus in six (24%) patients. Conclusions For GPitNETs that extend into the middle fossa, our study underscored the difficulties in surgical extraction and the necessity for tailored treatment approaches. To ensure the safest and most complete removal possible, the surgical strategy must be specifically adapted to each case. Additionally, employing a comprehensive support approach is essential to reduce the chance of complications in patients impacted by this condition.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38707178/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38707178</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066726/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066726</a> | DOI:<a href=https://doi.org/10.7759/cureus.57498>10.7759/cureus.57498</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38707178</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kenta Nakase</dc:creator>
<dc:creator>Fumihiko Nishimura</dc:creator>
<dc:creator>Shohei Yokoyama</dc:creator>
<dc:creator>Miho Kakutani</dc:creator>
<dc:creator>Taekyun Kim</dc:creator>
<dc:creator>Ryosuke Matsuda</dc:creator>
<dc:creator>Yasuhiro Takeshima</dc:creator>
<dc:creator>Shuichi Yamada</dc:creator>
<dc:creator>Young-Soo Park</dc:creator>
<dc:creator>Ichiro Nakagawa</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Cureus</dc:source>
<dc:title>Management Approaches and Patient Outcomes for Giant Pituitary Neuroendocrine Tumors Classified as Knosp Grade 3 and 4</dc:title>
<dc:identifier>pmid:38707178</dc:identifier>
<dc:identifier>pmc:PMC11066726</dc:identifier>
<dc:identifier>doi:10.7759/cureus.57498</dc:identifier>
</item>
<item>
<title>Concurrent Middle Cerebral Artery and Basilar Artery Occlusions Treated With Mechanical Thrombectomy in a Patient With Active COVID-19 Infection</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38707024/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>We report a rare case of acute ischemic stroke from concurrent large vessel occlusions (LVOs) and subsequent successful mechanical thrombectomy revascularization in a patient with active coronavirus disease 2019 (COVID-19) pneumonia. A 59-year-old woman presented to the emergency department after one week of intermittent chest pain, dyspnea, and diarrhea found to have COVID-19 pneumonia. On hospital day three, the patient developed acute altered mental status and hemiparesis with a National...</description>
<content:encoded><![CDATA[<div>Cureus. 2024 Apr 4;16(4):e57623. doi: 10.7759/cureus.57623. eCollection 2024 Apr.ABSTRACTWe report a rare case of acute ischemic stroke from concurrent large vessel occlusions (LVOs) and subsequent successful mechanical thrombectomy revascularization in a patient with active coronavirus disease 2019 (COVID-19) pneumonia. A 59-year-old woman presented to the emergency department after one week of intermittent chest pain, dyspnea, and diarrhea found to have COVID-19 pneumonia. On hospital day three, the patient developed acute altered mental status and hemiparesis with a National Institutes of Health Stroke Scale (NIHSS) of 22. CT with angiography demonstrated concurrent occlusions of the basilar artery and the M1 segment of the right middle cerebral artery (MCA) without intracranial hemorrhage. The patient was taken for urgent mechanical thrombectomy of the basilar artery, followed by the MCA, both of which were successful (thrombolysis in cerebral infarction (TICI) 3 and 2B) and timely. Despite early revascularization, the patient did not improve clinically with absent brainstem reflexes and a full MCA territorial infarct on imaging. This case describes a rare stroke syndrome of concurrent LVOs with rapid infarct progression despite timely revascularization. This example illustrates a severe cerebrovascular complication of active COVID-19 infection and the importance of vigilance regarding stroke prevention and neurological examination monitoring.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38707024/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38707024</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11070204/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11070204</a> | DOI:<a href=https://doi.org/10.7759/cureus.57623>10.7759/cureus.57623</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38707024</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Saarang Patel</dc:creator>
<dc:creator>Jeffrey Treiber</dc:creator>
<dc:creator>Jeremiah N Johnson</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Cureus</dc:source>
<dc:title>Concurrent Middle Cerebral Artery and Basilar Artery Occlusions Treated With Mechanical Thrombectomy in a Patient With Active COVID-19 Infection</dc:title>
<dc:identifier>pmid:38707024</dc:identifier>
<dc:identifier>pmc:PMC11070204</dc:identifier>
<dc:identifier>doi:10.7759/cureus.57623</dc:identifier>
</item>
<item>
<title>Effect of Pre-Antibiotic Use Before First Stroke Incidence on Recurrence and Mortality: A Longitudinal Study Using the Korean National Health Insurance Service Database</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38706744/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Our population-based longitudinal study revealed that pre-antibiotic use was associated with a higher risk of secondary stroke and a lower risk of mortality in the AIS and AHS groups. Further studies are needed to understand the relationship between dysbiosis and stroke outcomes.</description>
<content:encoded><![CDATA[<div>Int J Gen Med. 2024 Apr 29;17:1625-1633. doi: 10.2147/IJGM.S456925. eCollection 2024.ABSTRACTPURPOSE: Clinical studies on dysbiosis and stroke outcomes has been insufficient to establish clear evidence. This study aimed to investigate the effects of pre-antibiotic use before a stroke event on secondary outcomes using a longitudinal population-level database.PATIENTS AND METHODS: This retrospective cohort study included adults aged 55 years or older diagnosed with acute ischemic stroke (AIS) and acute hemorrhagic stroke (AHS) between 2004 and 2007. Patients were followed-up until the end of 2019, and the target outcomes were secondary AIS, AHS, and all-cause mortality. Multivariable Cox regression analyses were applied, and we adjusted covariates such as age, sex, socioeconomic status, hypertension, diabetes, and dyslipidemia. Pre-antibiotic use was identified from 7 days to 1 year before the acute stroke event.RESULTS: We included 159,181 patients with AIS (AIS group) and 49,077 patients with AHS (AHS group). Pre-antibiotic use significantly increased the risk of secondary AIS in the AIS group (adjusted hazard ratio [aHR], 1.03; 95% confidence interval [CI], 1.01-1.05; p = 0.009) and secondary AHS in the AHS group (aHR, 1.08; 95% CI, 1.03-1.12; p <0.001). Furthermore, pre-antibiotic use in the AIS group was associated with a lower risk of mortality (aHR, 0.95; 95% CI, 0.94-0.96; p <0.001).CONCLUSION: Our population-based longitudinal study revealed that pre-antibiotic use was associated with a higher risk of secondary stroke and a lower risk of mortality in the AIS and AHS groups. Further studies are needed to understand the relationship between dysbiosis and stroke outcomes.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38706744/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38706744</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11068048/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11068048</a> | DOI:<a href=https://doi.org/10.2147/IJGM.S456925>10.2147/IJGM.S456925</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38706744</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Dougho Park</dc:creator>
<dc:creator>Hyoung Seop Kim</dc:creator>
<dc:creator>Jong Hun Kim</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>International journal of general medicine</dc:source>
<dc:title>Effect of Pre-Antibiotic Use Before First Stroke Incidence on Recurrence and Mortality: A Longitudinal Study Using the Korean National Health Insurance Service Database</dc:title>
<dc:identifier>pmid:38706744</dc:identifier>
<dc:identifier>pmc:PMC11068048</dc:identifier>
<dc:identifier>doi:10.2147/IJGM.S456925</dc:identifier>
</item>
<item>
<title>Explore the value of carotid ultrasound radiomics nomogram in predicting ischemic stroke risk in patients with type 2 diabetes mellitus</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38706699/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: This study created a carotid ultrasound radiomics machine-learning-based IS risk nomogram for T2DM patients with carotid plaques. Its diagnostic performance and clinical prediction capabilities enable accurate, convenient, and customized medical care.</description>
<content:encoded><![CDATA[<div>Front Endocrinol (Lausanne). 2024 Apr 19;15:1357580. doi: 10.3389/fendo.2024.1357580. eCollection 2024.ABSTRACTBACKGROUND AND OBJECTIVE: Type 2 Diabetes Mellitus (T2DM) with insulin resistance (IR) is prone to damage the vascular endothelial, leading to the formation of vulnerable carotid plaques and increasing ischemic stroke (IS) risk. The purpose of this study is to develop a nomogram model based on carotid ultrasound radiomics for predicting IS risk in T2DM patients.METHODS: 198 T2DM patients were enrolled and separated into study and control groups based on IS history. After manually delineating carotid plaque region of interest (ROI) from images, radiomics features were identified and selected using the least absolute shrinkage and selection operator (LASSO) regression to calculate the radiomics score (RS). A combinatorial logistic machine learning model and nomograms were created using RS and clinical features like the triglyceride-glucose index. The three models were assessed using area under curve (AUC) and decision curve analysis (DCA).RESULTS: Patients were divided into the training set and the testing set by the ratio of 0.7. 4 radiomics features were selected. RS and clinical variables were all statically significant in the training set and were used to create a combination model and a prediction nomogram. The combination model (radiomics + clinical nomogram) had the largest AUC in both the training set and the testing set (0.898 and 0.857), and DCA analysis showed that it had a higher overall net benefit compared to the other models.CONCLUSIONS: This study created a carotid ultrasound radiomics machine-learning-based IS risk nomogram for T2DM patients with carotid plaques. Its diagnostic performance and clinical prediction capabilities enable accurate, convenient, and customized medical care.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38706699/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38706699</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11066235/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11066235</a> | DOI:<a href=https://doi.org/10.3389/fendo.2024.1357580>10.3389/fendo.2024.1357580</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38706699</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yusen Liu</dc:creator>
<dc:creator>Ying Kong</dc:creator>
<dc:creator>Yanhong Yan</dc:creator>
<dc:creator>Pinjing Hui</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Frontiers in endocrinology</dc:source>
<dc:title>Explore the value of carotid ultrasound radiomics nomogram in predicting ischemic stroke risk in patients with type 2 diabetes mellitus</dc:title>
<dc:identifier>pmid:38706699</dc:identifier>
<dc:identifier>pmc:PMC11066235</dc:identifier>
<dc:identifier>doi:10.3389/fendo.2024.1357580</dc:identifier>
</item>
<item>
<title>Sex Differences in Severity and Risk Factors for Ischemic Stroke in Patients With Hyperlipidemia</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38706531/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Increased ischemic stroke mortality risk score was associated with increased severity in both male and female AIS patients with hypertriglyceridemia. Our findings provide information about sex differences in specific risk factors that can be managed to improve the care of male and female ischemic stroke patients with hypertriglyceridemia.</description>
<content:encoded><![CDATA[<div>Neurosci Insights. 2024 May 3;19:26331055241246745. doi: 10.1177/26331055241246745. eCollection 2024.ABSTRACTOBJECTIVE: This study aims to determine sex differences in poststroke hypertriglyceridemia (serum triglyceride levels ⩾ 200 mg/dl) and high stroke severity in ischemic stroke patients.METHOD: Our study analyzed data from 392 males and 373 females with hypertriglyceridemia. Stroke severity on admission was measured using the National Institute of Health Stroke Scale (NIHSS) with a value ⩽7 indicating a more favorable post-stroke prognosis while a score of >7 indicates poorer post-stroke outcomes. Logistic regression models adjusted for demographic and risk factors. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for each clinical risk factor were used to predict the increasing odds of an association of a specific clinical baseline risk factor with the male or female AIS with hypertriglyceridemia.RESULTS: In the adjusted analysis, male patients with hypertriglyceridemia, diastolic blood pressure (OR = 1.100, 95% CI, 1.034-1.171, P = .002), and Ischemic stroke mortality (OR = 6.474, 95% CI, 3.262-12.847, P < .001) were significantly associated with increased stroke severity. In female patients with hypertriglyceridemia, age (OR = 0.920, 95% CI, 0.866-0.978, P = .008) was associated with reduced stroke severity, while ischemic stroke mortality score (OR = 37.477, 95% CI, 9.636-145.756, P < .001) was associated with increased stroke severity.CONCLUSION: Increased ischemic stroke mortality risk score was associated with increased severity in both male and female AIS patients with hypertriglyceridemia. Our findings provide information about sex differences in specific risk factors that can be managed to improve the care of male and female ischemic stroke patients with hypertriglyceridemia.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38706531/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38706531</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11069268/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11069268</a> | DOI:<a href=https://doi.org/10.1177/26331055241246745>10.1177/26331055241246745</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38706531</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Emmanuel Imeh-Nathaniel</dc:creator>
<dc:creator>Samuel Imeh-Nathaniel</dc:creator>
<dc:creator>Adebobola Imeh-Nathaniel</dc:creator>
<dc:creator>Oreoluwa Coker-Ayo</dc:creator>
<dc:creator>Nikhil Kulkarni</dc:creator>
<dc:creator>Thomas I Nathaniel</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Neuroscience insights</dc:source>
<dc:title>Sex Differences in Severity and Risk Factors for Ischemic Stroke in Patients With Hyperlipidemia</dc:title>
<dc:identifier>pmid:38706531</dc:identifier>
<dc:identifier>pmc:PMC11069268</dc:identifier>
<dc:identifier>doi:10.1177/26331055241246745</dc:identifier>
</item>
<item>
<title>Long-term Risk of Stroke After New-Onset Atrial Fibrillation in Sepsis Survivors: A 2-Year Follow-Up Study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38706156/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Cardiovascular complications such as new-onset atrial fibrillation (NOAF) are common in sepsis and are known to increase the risk of in-hospital mortality and stroke. However, only a handful of studies have evaluated the long-term risk of stroke after NOAF in sepsis survivors. As part of our efforts to address this issue, we conducted the first-ever follow-up study in a developing country evaluating the long-term risk of stroke for sepsis survivors following NOAF. Methods: This retrospective...</description>
<content:encoded><![CDATA[<div>J Intensive Care Med. 2024 May 5:8850666241251755. doi: 10.1177/08850666241251755. Online ahead of print.ABSTRACTCardiovascular complications such as new-onset atrial fibrillation (NOAF) are common in sepsis and are known to increase the risk of in-hospital mortality and stroke. However, only a handful of studies have evaluated the long-term risk of stroke after NOAF in sepsis survivors. As part of our efforts to address this issue, we conducted the first-ever follow-up study in a developing country evaluating the long-term risk of stroke for sepsis survivors following NOAF. Methods: This retrospective study evaluated all adult patients admitted at the Aga Khan University Hospital between July 2019 and December 2019 with the diagnosis of sepsis. Data was collected from medical records of the included patients. Outcome measures included in-hospital mortality and ischemic stroke within 2 years. Results: Seven hundred thirty patients were included in the study; 415 (57%) were males and 315 (43%) females; mean age was 59.4 ± 18 years. 59 (8%) patients developed NOAF. The risk of stroke within 2 years in sepsis survivors was 3.5%. Six out of 30 (20%) patients in the atrial fibrillation (AF) group developed stroke, whereas 11 out of 448 (2%) patients in the non-AF group developed stroke. NOAF was associated with an increased risk of ischemic stroke within 2 years (OR = 6.6; 95% CI, 2.3-12.8; P = <.001). Conclusion: We conclude that AF occurred frequently in sepsis patients and was also associated with a 6-fold increase in the risk of ischemic stroke within 2 years. Reliable interventions for identifying high-risk patients for ischemic stroke are still poorly characterized, and this study may serve as a basis for more extensive multicenter studies to identify patients at high risk for ischemic stroke in the aftermath of septic AF and develop precise interventions for preventing it.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38706156/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38706156</a> | DOI:<a href=https://doi.org/10.1177/08850666241251755>10.1177/08850666241251755</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38706156</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmed Ayaz</dc:creator>
<dc:creator>Muhammad Ibrahim</dc:creator>
<dc:creator>Ainan Arshad</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Journal of intensive care medicine</dc:source>
<dc:title>Long-term Risk of Stroke After New-Onset Atrial Fibrillation in Sepsis Survivors: A 2-Year Follow-Up Study</dc:title>
<dc:identifier>pmid:38706156</dc:identifier>
<dc:identifier>doi:10.1177/08850666241251755</dc:identifier>
</item>
<item>
<title>The Cerebroprotection and Prospects of FNDC5/irisin in Stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705569/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Stroke, the leading cause of disability and cognitive impairment, is also the second leading cause of death worldwide. The drugs with multi-targeted brain cytoprotective effects are increasingly being advocated for the treatment of stroke. Irisin, a newly discovered myokine produced by cleavage of fibronectin type III domain 5, has been shown to regulate glucose metabolism, mitochondrial energy, and fat browning. A large amount of evidence indicated that irisin could exert anti-inflammatory,...</description>
<content:encoded><![CDATA[<div>Neuropharmacology. 2024 May 3:109986. doi: 10.1016/j.neuropharm.2024.109986. Online ahead of print.ABSTRACTStroke, the leading cause of disability and cognitive impairment, is also the second leading cause of death worldwide. The drugs with multi-targeted brain cytoprotective effects are increasingly being advocated for the treatment of stroke. Irisin, a newly discovered myokine produced by cleavage of fibronectin type III domain 5, has been shown to regulate glucose metabolism, mitochondrial energy, and fat browning. A large amount of evidence indicated that irisin could exert anti-inflammatory, anti-apoptotic, and antioxidant properties in a variety of diseases such as myocardial infarction, inflammatory bowel disease, lung injury, and kidney or liver disease. Studies have found that irisin is widely distributed in multiple brain regions and also plays an important regulatory role in the central nervous system. The most common cause of a stroke is a sudden blockage of an artery (ischemic stroke), and in some circumstances, a blood vessel rupture can also result in a stroke (hemorrhagic stroke). After a stroke, complicated pathophysiological processes lead to serious brain injury and neurological dysfunction. According to recent investigations, irisin may protect elements of the neurovascular unit by acting on multiple pathological processes in stroke. This review aims to outline the currently recognized effects of irisin on stroke and propose possible directions for future research.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705569/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705569</a> | DOI:<a href=https://doi.org/10.1016/j.neuropharm.2024.109986>10.1016/j.neuropharm.2024.109986</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705569</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuanyuan Liu</dc:creator>
<dc:creator>Yang Liu</dc:creator>
<dc:creator>Xiangyu Zhang</dc:creator>
<dc:creator>Gaili Yan</dc:creator>
<dc:creator>Lingxiao Qi</dc:creator>
<dc:creator>V Wee Yong</dc:creator>
<dc:creator>Mengzhou Xue</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Neuropharmacology</dc:source>
<dc:title>The Cerebroprotection and Prospects of FNDC5/irisin in Stroke</dc:title>
<dc:identifier>pmid:38705569</dc:identifier>
<dc:identifier>doi:10.1016/j.neuropharm.2024.109986</dc:identifier>
</item>
<item>
<title>Spinal lipocalin 2 as a factor in the development of central post-stroke pain</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705557/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Central poststroke pain (CPSP) is a type of central neuropathic pain whose mechanisms remain unknown. Recently, we showed that activated astrocytes and microglial cells are present in the spinal cord of CPSP model mice. Activated glial cells exacerbate cerebral ischemic pathology by increasing the expression of inflammatory factors. However, the involvement of spinal glial cells in CPSP remains unknown. We hypothesized that spinal glial cell-derived molecules cause hyperexcitability or promoted...</description>
<content:encoded><![CDATA[<div>Brain Res. 2024 May 3:148976. doi: 10.1016/j.brainres.2024.148976. Online ahead of print.ABSTRACTCentral poststroke pain (CPSP) is a type of central neuropathic pain whose mechanisms remain unknown. Recently, we showed that activated astrocytes and microglial cells are present in the spinal cord of CPSP model mice. Activated glial cells exacerbate cerebral ischemic pathology by increasing the expression of inflammatory factors. However, the involvement of spinal glial cells in CPSP remains unknown. We hypothesized that spinal glial cell-derived molecules cause hyperexcitability or promoted the development of CPSP. In this study, we identified glial cell-derived factors involved in the development of CPSP using a bilateral common carotid occlusion (BCAO)-induced CPSP mouse model. Male ddY mice were subjected to BCAO for 30 min. The von Frey test assessed mechanical hypersensitivity in the right hind paw of mice. BCAO mice showed hypersensitivity to mechanical stimuli and astrocyte activation in the spinal cord 3 days after treatment. DNA microarray analysis revealed a significant increase in lipocalin 2 (LCN2), is known as neutrophil gelatinase-associated lipocalin, in the superficial dorsal horns of BCAO-induced CPSP model mice. LCN2 colocalized with GFAP, an astrocyte marker. Spinal GFAP-positive cells in BCAO mice co-expressed signal transducer and activator of transcription 3 (STAT3). The increase in the fluorescence intensity of LCN2 and GFAP in BCAO mice was suppressed by intrathecal injection of AG490, an inhibitor of JAK2 and downstream STAT3 activation, or anti-LCN2 antibody. Our findings indicated that LCN2 in spinal astrocytes may be a key molecule and may be partly involved in the development of CPSP.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705557/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705557</a> | DOI:<a href=https://doi.org/10.1016/j.brainres.2024.148976>10.1016/j.brainres.2024.148976</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705557</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kazuo Nakamoto</dc:creator>
<dc:creator>Shogo Tokuyama</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Brain research</dc:source>
<dc:title>Spinal lipocalin 2 as a factor in the development of central post-stroke pain</dc:title>
<dc:identifier>pmid:38705557</dc:identifier>
<dc:identifier>doi:10.1016/j.brainres.2024.148976</dc:identifier>
</item>
<item>
<title>Early vs Late Anticoagulation in Acute Ischemic Stroke with Indications Outside Atrial Fibrillation</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705498/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: Early anticoagulation (i.e., ≤ 3 days) in non-atrial fibrillation ischemic stroke patients with an emergent indication may be safe and carry a lower risk of thromboembolic complications than later anticoagulation.</description>
<content:encoded><![CDATA[<div>J Stroke Cerebrovasc Dis. 2024 May 3:107757. doi: 10.1016/j.jstrokecerebrovasdis.2024.107757. Online ahead of print.ABSTRACTBACKGROUND: Current literature lacks guidance on the safety of administering anticoagulation in acute ischemic stroke with emergent indications that require anticoagulation other than atrial fibrillation. Therefore, we tend to rely on studies investigating acute ischemic stroke in atrial fibrillation for anticoagulation recommendations.METHODS: We retrospectively reviewed data for patients with acute ischemic stroke who had a non-atrial fibrillation emergent indication for anticoagulation (e.g., intra-arterial thrombus, intracardiac thrombus, acute coronary syndrome, acute limb ischemia, deep vein thrombosis and pulmonary embolism) diagnosed within 3 days of acute ischemic stroke. Patients who received anticoagulation ≤ 3 days of stroke onset (Group A) were compared to those who either received it afterwards or did not receive it at all (Group B).RESULTS: Out of the 558 patients, only 88 patients met our inclusion criteria. Of the total cohort, 55.7% patients were males, and basic demographics were similar in both groups except for milder strokes in Group A (national institute of health stroke scale 6 vs. 12.5, p = 0.03). Only 2 patients in Group A and 1 patient in Group B developed intracranial hemorrhage, which was not statistically significant. Group A patients had a lower incidence of both new diagnosis (2% vs. 34.2% %, p < 0.001) and propagation of an established venous thromboembolism. They also had a lower rate of any thromboembolic complication (2% vs. 42%, p < 0.001).CONCLUSION: Early anticoagulation (i.e., ≤ 3 days) in non-atrial fibrillation ischemic stroke patients with an emergent indication may be safe and carry a lower risk of thromboembolic complications than later anticoagulation.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705498/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705498</a> | DOI:<a href=https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107757>10.1016/j.jstrokecerebrovasdis.2024.107757</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705498</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ammar Jumah</dc:creator>
<dc:creator>Siyuan Fu</dc:creator>
<dc:creator>Abdalla Jamal Albanna</dc:creator>
<dc:creator>Utkarsh Agarwal</dc:creator>
<dc:creator>Michael Fana</dc:creator>
<dc:creator>Omar Choudhury</dc:creator>
<dc:creator>Anas Idris</dc:creator>
<dc:creator>Abdelrahman Elfaham</dc:creator>
<dc:creator>Zahid Iqbal</dc:creator>
<dc:creator>Lonni Schultz</dc:creator>
<dc:creator>Katie Latack</dc:creator>
<dc:creator>Megan Brady</dc:creator>
<dc:creator>Dawn Scozzari</dc:creator>
<dc:creator>Ahmad Riad Ramadan</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</dc:source>
<dc:title>Early vs Late Anticoagulation in Acute Ischemic Stroke with Indications Outside Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38705498</dc:identifier>
<dc:identifier>doi:10.1016/j.jstrokecerebrovasdis.2024.107757</dc:identifier>
</item>
<item>
<title>Plasma lipidome differences in patients with and without significant carotid plaque</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705432/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Plasma lipidomes measured by liquid chromatography-mass spectrometry show differences in patients with stable and unstable carotid plaques, therefore these compounds could potentially be used as biomarkers for unstable plaque in future clinical diagnosis.</description>
<content:encoded><![CDATA[<div>Vascul Pharmacol. 2024 May 3:107377. doi: 10.1016/j.vph.2024.107377. Online ahead of print.ABSTRACTBACKGROUND: Atherosclerosis is a major cause of ischemic stroke, and early detection of advanced atherosclerosis in the carotid artery is important for reducing morbidity and mortality. What is even more important is not only detection of atherosclerosis but early determination whether the patients are at high risk of an event with adverse effects as the size of the plaque does not necessarily reflect its potential to trigger such events.AIM: We studied whether plasma lipidomics profile can be used as a diagnostic tool for stratification of stable or unstable plaques without the need of removing the carotid plaque.METHODS: This study used liquid chromatography high-resolution tandem mass spectrometry lipidomics to characterize lipid profiles in patients' plasma and found that patients with significant and complicated (vulnerable) atherosclerotic plaque had distinct lipid profiles compared to those with insignificant plaques.RESULTS: The lipid classes that were most predictive of vulnerable plaque were lysophosphoethanolamines, fatty acyl esters of hydroxy fatty acids, free fatty acids, plasmalogens, and triacylglycerols. Most of these compounds were found decreased in plasma of patients with unstable plaques which enabled sufficient performance of a statistical model used for patient stratification.CONCLUSIONS: Plasma lipidomes measured by liquid chromatography-mass spectrometry show differences in patients with stable and unstable carotid plaques, therefore these compounds could potentially be used as biomarkers for unstable plaque in future clinical diagnosis.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705432/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705432</a> | DOI:<a href=https://doi.org/10.1016/j.vph.2024.107377>10.1016/j.vph.2024.107377</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705432</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin Malý</dc:creator>
<dc:creator>Ondřej Kučerka</dc:creator>
<dc:creator>Kamila Bechyňská</dc:creator>
<dc:creator>Karolína Kočí</dc:creator>
<dc:creator>Václav Mandys</dc:creator>
<dc:creator>Jana Hajšlová</dc:creator>
<dc:creator>Vít Kosek</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Vascular pharmacology</dc:source>
<dc:title>Plasma lipidome differences in patients with and without significant carotid plaque</dc:title>
<dc:identifier>pmid:38705432</dc:identifier>
<dc:identifier>doi:10.1016/j.vph.2024.107377</dc:identifier>
</item>
<item>
<title>Thiazolidinediones Decrease the Recurrence of Intracerebral Hemorrhage in Type 2 Diabetes Mellitus Patients: A Nested Case-Control Study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705143/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: The use of TZD in patients with T2DM was associated with a lower risk of subsequent HS and mortality following ICH.</description>
<content:encoded><![CDATA[<div>Neuroepidemiology. 2024 May 3. doi: 10.1159/000539001. Online ahead of print.ABSTRACTINTRODUCTION: Preclinical evidence demonstrated the therapeutic potential of TZDs for the treatment of intracerebral hemorrhage (ICH). The present study conducted an investigation of cerebrovascular and cardiovascular outcomes following ICH in patients with type 2 diabetes mellitus (T2DM) treated with or without TZDs.METHODS: This retrospective nested case-control study used data from the Taiwan National Health Insurance Research Database. A total of 62,515 T2DM patients who were hospitalized with a diagnosis of ICH were enrolled, including 7,603 TZD users. Data for TZD non-users were extracted using propensity score matching. Primary outcomes included death and major adverse cardiovascular events (MACEs), which were defined as a composite of ischemic stroke, hemorrhagic stroke (HS), acute myocardial infarction (AMI), and congestive heart failure (CHF). Patients aged < 20 years with a history of traumatic brain injury or any prior history of MACEs were excluded.RESULTS: TZD users had significantly lower MACE risks compared with TZD non-users following ICH (adjusted hazard ratio [aHR]: 0.90, 95% confidence interval [CI]: 0.85-0.94, p < 0.001). The most significant MACE difference reported for TZD users was HS, which possessed lower incidence than in TZD non-users, especially for the events that happened within 3 months following ICH (aHR: 0.74, 95% CI: 0.62-0.89 within one month, p < 0.01; aHR: 0.68, 95% CI: 0.54-0.85 between 1-3 month).CONCLUSION: The use of TZD in patients with T2DM was associated with a lower risk of subsequent HS and mortality following ICH.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705143/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705143</a> | DOI:<a href=https://doi.org/10.1159/000539001>10.1159/000539001</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705143</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Cheng-Di Chiu</dc:creator>
<dc:creator>You-Pen Chiu</dc:creator>
<dc:creator>Hei-Tung Yip</dc:creator>
<dc:creator>Hui-Ru Ji</dc:creator>
<dc:creator>Der-Yang Cho</dc:creator>
<dc:creator>Irene Han-Juo Cheng</dc:creator>
<dc:creator>Cho-Yi Chen</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Neuroepidemiology</dc:source>
<dc:title>Thiazolidinediones Decrease the Recurrence of Intracerebral Hemorrhage in Type 2 Diabetes Mellitus Patients: A Nested Case-Control Study</dc:title>
<dc:identifier>pmid:38705143</dc:identifier>
<dc:identifier>doi:10.1159/000539001</dc:identifier>
</item>
<item>
<title>Myocardial Infarction in Chronic Myeloid Leukemia: Results from Nationwide Readmission Database</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705141/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Background and Objective Chronic myeloid leukemia (CML) is a hematological malignancy with an excellent prognostic outcome. After advancements in CML treatment and the introduction of different tyrosine kinase inhibitors (TKI), the life expectancy of CML patients has become equivalent to that of the general population. As a result, coronary artery disease is anticipated to be the leading cause of death among CML patients. Moreover, TKI use is associated with a risk of endothelial dysfunction,...</description>
<content:encoded><![CDATA[<div>Oncology. 2024 May 3. doi: 10.1159/000539149. Online ahead of print.ABSTRACTBackground and Objective Chronic myeloid leukemia (CML) is a hematological malignancy with an excellent prognostic outcome. After advancements in CML treatment and the introduction of different tyrosine kinase inhibitors (TKI), the life expectancy of CML patients has become equivalent to that of the general population. As a result, coronary artery disease is anticipated to be the leading cause of death among CML patients. Moreover, TKI use is associated with a risk of endothelial dysfunction, thrombosis, and cardiovascular events, including myocardial infarction. In this study, we compare the outcomes of percutaneous coronary intervention (PCI) in patients with CML to their matched non-CML counterparts. and compare the events reported with different TKI. Method The Nationwide Readmission Database (NRD) was searched from January 2016 to December 2020. for the study population. Adults of age ≥ 18 years with or without CML hospitalized for with a primary diagnosis of acute myocardial infarction, ST-segment elevation myocardial infarction (STEMI), and non-ST-segment elevation myocardial infarction (NSTEMI) and underwent PCI were included. The patients were identified using ICD-10 codes. The baseline characteristics and outcomes of the CML and non-CML patients who underwent PCI were compared. The primary outcomes were in-hospital mortality and 30-day readmission rates. The secondary outcomes were the PCI complications rates. Data regarding TKI reports of STEMI and acute coronary syndrome were obtained from The FDA Adverse Event Reporting System (FARES). Results Out of 2,727,619 patients with myocardial infarction, 2,124 CML patients were identified. A total of 888 CML patients underwent PCI. The mean age was 68.34 ± 11.14, with 62.46 % above 65 years. The analysis showed no significant difference between CML and non-CML patients after PCI for death (OR? 0.93 (95% CI 0.49-1.80), P=0.527) and 30-day readmission (OR? 1.41 (95% CI 0.99-2.01), P=0.056) rates. CML patients were significantly older (mean age 68.34 ± 11.14 versus 64.40 ± 12.61, p &lt; 0.001) than non-CML patients without a difference in sex distribution. Hypertension (85.45% versus 78.64%), diabetes (45.48% versus 37.29), stroke (11.84% versus 7.78) at baseline were significantly higher in CML group. Prior myocardial infarction events (20.51% versus 15.17%) and prior PCI procedure (24.47% versus 16.89%) were significantly higher in CML group. CML had a significantly longer hospital stay (4.66 ± 4.40 versus 3.75 ± 4.62 days, p = 0.001). The primary outcomes did not differ between the comparison groups. Conclusion This analysis showed no statistically significant difference in mortality, 30-day readmission, and complication rates post PCI between CML and non-CML patients. However, interestingly, CML patients may experience lower coronary artery dissection and ischemic stroke rates than those without CML diagnosis.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705141/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705141</a> | DOI:<a href=https://doi.org/10.1159/000539149>10.1159/000539149</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705141</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Elrazi A Ali</dc:creator>
<dc:creator>Neel Patel</dc:creator>
<dc:creator>Mazin Khalid</dc:creator>
<dc:creator>Rasha Kaddoura</dc:creator>
<dc:creator>Madhumathi Kalavar</dc:creator>
<dc:creator>Jacob Shani</dc:creator>
<dc:creator>Mohamed Yassin</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Oncology</dc:source>
<dc:title>Myocardial Infarction in Chronic Myeloid Leukemia: Results from Nationwide Readmission Database</dc:title>
<dc:identifier>pmid:38705141</dc:identifier>
<dc:identifier>doi:10.1159/000539149</dc:identifier>
</item>
<item>
<title>Clinical significance of intracranial hemorrhage after thrombectomy detected solely by magnetic resonance imaging and not by computed tomography</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38705135/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: ICH detected by MRI alone did not influence clinical outcomes in patients with LVO treated with MT.</description>
<content:encoded><![CDATA[<div>J Neurol Sci. 2024 Apr 12;460:122999. doi: 10.1016/j.jns.2024.122999. Online ahead of print.ABSTRACTBACKGROUND AND OBJECTIVE: Whether intracranial hemorrhage (ICH) detected using magnetic resonance imaging (MRI) affects the clinical outcomes of patients with large-vessel occlusion (LVO) treated with mechanical thrombectomy (MT) remains unclear. This study investigated the clinical features of ICH after MT detected solely by MRI.METHODS: This was a retrospective analysis of patients with acute ischemic stroke and occlusion of the internal carotid artery or middle cerebral artery treated with MT between April 2011 and March 2021. Among 632 patients, patients diagnosed with no ICH using CT, with a pre-morbid modified Rankin Scale (mRS) score ≤ 2, and those who underwent MRI including T2* and computed tomography (CT) within 72 h from MT were enrolled. The main outcomes were the association between ICH detected solely by MRI and clinical outcomes at 90 days. Poor clinical outcomes were defined as mRS score > 2 at 90 days after onset.RESULTS: Of the 246 patients, 29 (12%) had ICH on MRI (MRI-ICH(+)), and 217 (88%) were MRI-ICH(-). There was no significant difference between number of patients with MRI-ICH(+) experiencing poor (10 [12%]) and favorable (19 [12%]) outcomes. The mRS score at 90 days between patients with MRI-ICH (+) and MRI-ICH(-) was not significantly different (2 [1-4] vs. 2 [1-4], respectively). Higher age and lower ASPECTS were independent risk factors for poor outcomes, as shown by multivariate regression analysis. MRI-ICH(+) status was not associated with poor outcomes.CONCLUSIONS: ICH detected by MRI alone did not influence clinical outcomes in patients with LVO treated with MT.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38705135/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38705135</a> | DOI:<a href=https://doi.org/10.1016/j.jns.2024.122999>10.1016/j.jns.2024.122999</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38705135</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kentaro Suzuki</dc:creator>
<dc:creator>Takehiro Katano</dc:creator>
<dc:creator>Shinichiro Numao</dc:creator>
<dc:creator>Yuji Nishi</dc:creator>
<dc:creator>Akihito Kutsuna</dc:creator>
<dc:creator>Takuya Kanamaru</dc:creator>
<dc:creator>Tomonari Saito</dc:creator>
<dc:creator>Junya Aoki</dc:creator>
<dc:creator>Yasuhiro Nishiyama</dc:creator>
<dc:creator>Kazumi Kimura</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Journal of the neurological sciences</dc:source>
<dc:title>Clinical significance of intracranial hemorrhage after thrombectomy detected solely by magnetic resonance imaging and not by computed tomography</dc:title>
<dc:identifier>pmid:38705135</dc:identifier>
<dc:identifier>doi:10.1016/j.jns.2024.122999</dc:identifier>
</item>
<item>
<title>Research progress of prodrugs for the treatment of cerebral ischemia</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38704941/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>It is well-known that pharmacotherapy plays a pivotal role in the treatment and prevention of cerebral ischemia. Nevertheless, existing drugs, including numerous natural products, encounter various challenges when applied in cerebral ischemia treatment. These challenges comprise poor brain absorption due to low blood-brain barrier (BBB) permeability, limited water solubility, inadequate bioavailability, poor stability, and rapid metabolism. To address these issues, researchers have turned to...</description>
<content:encoded><![CDATA[<div>Eur J Med Chem. 2024 May 1;272:116457. doi: 10.1016/j.ejmech.2024.116457. Online ahead of print.ABSTRACTIt is well-known that pharmacotherapy plays a pivotal role in the treatment and prevention of cerebral ischemia. Nevertheless, existing drugs, including numerous natural products, encounter various challenges when applied in cerebral ischemia treatment. These challenges comprise poor brain absorption due to low blood-brain barrier (BBB) permeability, limited water solubility, inadequate bioavailability, poor stability, and rapid metabolism. To address these issues, researchers have turned to prodrug strategies, aiming to mitigate or eliminate the adverse properties of parent drug molecules. In vivo metabolism or enzymatic reactions convert prodrugs into active parent drugs, thereby augmenting BBB permeability, improving bioavailability and stability, and reducing toxicity to normal tissues, ultimately aiming to enhance treatment efficacy and safety. This comprehensive review delves into multiple effective prodrug strategies, providing a detailed description of representative prodrugs developed over the past two decades. It underscores the potential of prodrug approaches to improve the therapeutic outcomes of currently available drugs for cerebral ischemia. The publication of this review serves to enrich current research progress on prodrug strategies for the treatment and prevention of cerebral ischemia. Furthermore, it seeks to offer valuable insights for pharmaceutical chemists in this field, offer guidance for the development of drugs for cerebral ischemia, and provide patients with safer and more effective drug treatment options.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38704941/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38704941</a> | DOI:<a href=https://doi.org/10.1016/j.ejmech.2024.116457>10.1016/j.ejmech.2024.116457</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38704941</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Hongwei Zheng</dc:creator>
<dc:creator>Hongmei Wu</dc:creator>
<dc:creator>Dezhi Wang</dc:creator>
<dc:creator>Sijia Wang</dc:creator>
<dc:creator>Dongliang Ji</dc:creator>
<dc:creator>Xiao Liu</dc:creator>
<dc:creator>Ge Gao</dc:creator>
<dc:creator>Xing Su</dc:creator>
<dc:creator>Yanan Zhang</dc:creator>
<dc:creator>Yong Ling</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>European journal of medicinal chemistry</dc:source>
<dc:title>Research progress of prodrugs for the treatment of cerebral ischemia</dc:title>
<dc:identifier>pmid:38704941</dc:identifier>
<dc:identifier>doi:10.1016/j.ejmech.2024.116457</dc:identifier>
</item>
<item>
<title>Fabrication of Shape Memory Polymer Endovascular Thrombectomy Device for Treating Ischemic Stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38704791/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Stroke is the second result for death and ischemic stroke constitutes most of all stroke cases. Ischemic stroke takes place when blood clot or embolus blocks cerebral vessel and interrupts blood flow, which often leads to brain damage, permanent disability, or death. There is a 4.5-hour (golden hour) treatment window to restore blood flow prior to permanent neurological impairment results. Current treatments of stroke consist mechanical system or thrombolytic drug therapy to disrupt or dissolve...</description>
<content:encoded><![CDATA[<div>Macromol Rapid Commun. 2024 May 5:e2400146. doi: 10.1002/marc.202400146. Online ahead of print.ABSTRACTStroke is the second result for death and ischemic stroke constitutes most of all stroke cases. Ischemic stroke takes place when blood clot or embolus blocks cerebral vessel and interrupts blood flow, which often leads to brain damage, permanent disability, or death. There is a 4.5-hour (golden hour) treatment window to restore blood flow prior to permanent neurological impairment results. Current treatments of stroke consist mechanical system or thrombolytic drug therapy to disrupt or dissolve thrombus. Thrombolytics given more than 4.5 h after initial onset of symptoms are not effective on all thrombi. Also, the drugs may cause intracranial hemorrhage, which may be severe or fatal. New treatment modality should improve mortality rates and decrease morbidity. An effective treatment method should be easy, fast to deploy and resolve thrombus faster than current therapies. Promising method for treatment of stroke is mechanical retrieving of thrombi employing device deployed endovascularly. Advent of smart materials has led to research fabrication of several minimally invasive endovascular devices that take advantage of new materials capabilities. One of these capabilities is shape memory, is capability of material to store temporary form, then activate to primary shape as subjected to stimuli. Shape memory polymers (SMPs) have been employed as good materials for thrombectomy device fabrication. Therefore, current review presents thrombectomy device development with SMPs and fabrication of SMP-based devices for improving stroke treatment is also described. Design, performance, limitations, and in vitro or in vivo clinical results of SMP-based thrombectomy devices are identified. Furthermore, future directions of SMP-based thrombectomy devices are highlighted. Review also sheds light on SMP's future outlook and recommendations for thrombectomy device application, opening a new era for advanced materials in materials science. This will demonstrate how new approaches can be achieved employing the latest trends in research world in the development of advanced SMP materials. This article is protected by copyright. All rights reserved.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38704791/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38704791</a> | DOI:<a href=https://doi.org/10.1002/marc.202400146>10.1002/marc.202400146</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38704791</guid>
<pubDate>Sun, 05 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Emel Kuram</dc:creator>
<dc:creator>Hasan Hüseyin Karadeli</dc:creator>
<dc:date>2024-05-05</dc:date>
<dc:source>Macromolecular rapid communications</dc:source>
<dc:title>Fabrication of Shape Memory Polymer Endovascular Thrombectomy Device for Treating Ischemic Stroke</dc:title>
<dc:identifier>pmid:38704791</dc:identifier>
<dc:identifier>doi:10.1002/marc.202400146</dc:identifier>
</item>
<item>
<title>Incidence of recurrent ischemic stroke and its associated factors in a tertiary care center in Thailand: a retrospective cohort study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38704525/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSION: The incidence rate of the recurrence was moderate in our tertiary care setting, with a decreasing trend over time after the first episode. The various subtypes of IS and smoking status can lead to differences in event-free survival probabilities.</description>
<content:encoded><![CDATA[<div>BMC Neurol. 2024 May 4;24(1):152. doi: 10.1186/s12883-024-03640-0.ABSTRACTBACKGROUND: Ischemic stroke (IS) is one of the leading causes of death among non-communicable diseases in Thailand. Patients who have survived an IS are at an increased risk of developing recurrent IS, which can result in worse outcomes and post-stroke complications.OBJECTIVES: The study aimed to investigate the incidence of recurrent IS among patients with first-ever IS during a one-year follow-up period and to determine its associated risk factors.METHODS: Adult patients (aged ≥ 18 years) who were hospitalized at the Stroke Center, King Chulalongkorn Memorial Hospital (KCMH) in Bangkok, Thailand, due to first-ever IS between January and December 2019 and had at least one follow-up visit during the one-year follow-up period were included in this retrospective cohort study. IS diagnosis was confirmed by neurologists and imaging. The log-rank test was used to determine the event-free survival probabilities of recurrent IS in each risk factor.RESULTS: Of 418 patients hospitalized due to first-ever IS in 2019, 366 (87.6%) were included in the analysis. During a total of 327.2 person-years of follow-up, 25 (6.8%) patients developed recurrent IS, accounting for an incidence rate of 7.7 per 100 person-year (95% confidence interval [CI] 5.2-11.3). The median (interquartile range) time of recurrence was 35 (16-73) days. None of the 47 patients with atrial fibrillation developed recurrent IS. The highest incidence rate of recurrent IS occurred within 1 month after the first episode (34 per 100 person-years) compared to other follow-up periods. Patients with small vessel occlusion and large-artery atherosclerosis (LAA) constituted the majority of patients in the recurrent IS episode (48% and 40%, respectively), with LAA exhibiting a higher recurrence rate (13.5%). Additionally, smoking status was found to be associated with an increased risk of recurrence.CONCLUSION: The incidence rate of the recurrence was moderate in our tertiary care setting, with a decreasing trend over time after the first episode. The various subtypes of IS and smoking status can lead to differences in event-free survival probabilities.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38704525/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38704525</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11069183/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">PMC11069183</a> | DOI:<a href=https://doi.org/10.1186/s12883-024-03640-0>10.1186/s12883-024-03640-0</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38704525</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Thanapoom Taweephol</dc:creator>
<dc:creator>Pitsinee Saksit</dc:creator>
<dc:creator>Akarin Hiransuthikul</dc:creator>
<dc:creator>Pongpat Vorasayan</dc:creator>
<dc:creator>Wasan Akarathanawat</dc:creator>
<dc:creator>Aurauma Chutinet</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>BMC neurology</dc:source>
<dc:title>Incidence of recurrent ischemic stroke and its associated factors in a tertiary care center in Thailand: a retrospective cohort study</dc:title>
<dc:identifier>pmid:38704525</dc:identifier>
<dc:identifier>pmc:PMC11069183</dc:identifier>
<dc:identifier>doi:10.1186/s12883-024-03640-0</dc:identifier>
</item>
<item>
<title>Sociodemographic Predictors of Hypertensive Crisis in the Hospitalized Population in the United States</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38704130/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Being of a minority population, male sex, low-income status, and uninsured were associated with a higher likelihood of hypertensive crisis. Blacks were the youngest and had the highest risk of end-organ damage. Targeted interventions and healthcare policies should be implemented to address these disparities and enhance patient outcomes.</description>
<content:encoded><![CDATA[<div>Curr Probl Cardiol. 2024 May 2:102610. doi: 10.1016/j.cpcardiol.2024.102610. Online ahead of print.ABSTRACTINTRODUCTION: Hypertensive crisis (HC) encompasses hypertensive emergencies (HE) and urgencies (HU). Recent literature on HC's social determinants (SD) and racial disparities (RD) of the inpatient population is scarce. We aimed to examine these factors.METHODS: A retrospective analysis of the 2016-2020 National Inpatient Sample was conducted, and all hospitalizations for HC were identified with their ICD-10 codes. A probability estimation of outcomes was calculated by performing multivariable logistic regression analysis, which took confounders into account. Our primary outcomes were SDs of HC. Secondary outcomes were myocardial infarction (MI), stroke, acute kidney injury (AKI), and transient ischemic attack (TIA).RESULTS: The minority populations were more likely than the Caucasians to be diagnosed with HCs: Blacks 2.7 (2.6-2.9), Hispanics 1.2 (1.2-1.3), and Asians 1.4 (1.3-1.5),(p<0.0001, all). Furthermore, being male 1.1 (1.09-1.2, p<0.0001), those with 'self-pay' insurance 1.02 (1.01-1.03, p<0.0001), and those in the <25th percentile of median household income 1.3 (1.2-1.3, p<0.0001), were more likely to be diagnosed with HCs. The Black population had the highest likelihood of end-organ damage: MI 2.7 (2.6-2.9), Stroke 3.2 (3.1-3.4), AKI 2.4 (2.2-2.5), and TIA 2.8 (2.7-3.0), (p<0.0001, all), compared to their Caucasian counterpart.CONCLUSIONS: Being of a minority population, male sex, low-income status, and uninsured were associated with a higher likelihood of hypertensive crisis. Blacks were the youngest and had the highest risk of end-organ damage. Targeted interventions and healthcare policies should be implemented to address these disparities and enhance patient outcomes.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38704130/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38704130</a> | DOI:<a href=https://doi.org/10.1016/j.cpcardiol.2024.102610>10.1016/j.cpcardiol.2024.102610</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38704130</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Endurance Evbayekha</dc:creator>
<dc:creator>Yetunde Ishola</dc:creator>
<dc:creator>Ovie Okorare</dc:creator>
<dc:creator>Assumpta Chike</dc:creator>
<dc:creator>Sheeba AbrahamMBBS</dc:creator>
<dc:creator>Adaeze Vivian Aneke</dc:creator>
<dc:creator>Joshua T Green</dc:creator>
<dc:creator>Adenuga Ebunoluwa Grace</dc:creator>
<dc:creator>Cece E Ibeson</dc:creator>
<dc:creator>Evidence Eseose Ohikhuai Bpharm</dc:creator>
<dc:creator>Okelue E Okobi</dc:creator>
<dc:creator>Pius Ouwatosin Akande</dc:creator>
<dc:creator>Patience Nwafor</dc:creator>
<dc:creator>Tamunoinemi Bob-Manuel</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Current problems in cardiology</dc:source>
<dc:title>Sociodemographic Predictors of Hypertensive Crisis in the Hospitalized Population in the United States</dc:title>
<dc:identifier>pmid:38704130</dc:identifier>
<dc:identifier>doi:10.1016/j.cpcardiol.2024.102610</dc:identifier>
</item>
<item>
<title>Prognostic implications of left ventricular hypertrophy and mechanical function in Fabry disease: A longitudinal cohort study</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38704103/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Sex-specific grading of LVH by LVMI is practical for risk stratification in patients with Fabry disease, and impaired LV GLS further refines the prognostication.</description>
<content:encoded><![CDATA[<div>J Am Soc Echocardiogr. 2024 May 2:S0894-7317(24)00200-1. doi: 10.1016/j.echo.2024.04.010. Online ahead of print.ABSTRACTBACKGROUND: The prognostic value of different grades of left ventricular hypertrophy (LVH) and left ventricular (LV) mechanical function in Fabry disease is unclear. We aimed to evaluate the association between the severity of LVH, LV mechanical function, and clinical outcomes in Fabry disease.METHODS: We conducted a retrospective cohort study from a single-center registry of adult patients with Fabry disease. LV mass index (LVMI) was measured by echocardiography. The severity of LVH was categorized by LVMI using the sex-specific cutoff values. LV mechanical function was measured as LV global longitudinal strain (GLS) by speckle tracking analysis. The primary outcome was a composite of major adverse cardiovascular events (MACE) at 5 years, including heart failure hospitalization, sustained ventricular tachycardia, acute ischemic stroke, and all-cause mortality.RESULTS: The study included 268 patients (age 50.4 ± 15.4 years, men 46.6%) with Fabry disease (83.2% IVS4+919G>A mutation) , and 106 patients (39.6%) had LVH. Patients with mild, moderate, or severe LVH had 5-year MACE rates of 7.4%, 10%, and 30.5%, respectively (P< 0.001). Moreover, patients with impaired LV GLS (<14.1%) had a higher 5-year MACE rate than those with preserved LV GLS (32.1% vs. 2.4%, P< 0.001). Severe LVH was an independent predictor of MACE as compared with those without LVH (adjusted hazard ratio, 12.73; 95% confidence interval, 1.3-124.71; P= 0.03), after adjusting for age, sex, hypertension, hyperlipidemia, atrial fibrillation, renal function, average E/e', enzyme replacement therapy (ERT), and LV GLS. Patients with severe LVH and impaired LV GLS had the highest incidence for MACE (log-rank P< 0.05), irrespective of sex, genotypes, and whether receiving ERT or not.CONCLUSIONS: Sex-specific grading of LVH by LVMI is practical for risk stratification in patients with Fabry disease, and impaired LV GLS further refines the prognostication.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38704103/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38704103</a> | DOI:<a href=https://doi.org/10.1016/j.echo.2024.04.010>10.1016/j.echo.2024.04.010</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38704103</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Hao-Chih Chang</dc:creator>
<dc:creator>Ling Kuo</dc:creator>
<dc:creator>Shih-Hsien Sung</dc:creator>
<dc:creator>Dau-Ming Niu</dc:creator>
<dc:creator>Wen-Chung Yu</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</dc:source>
<dc:title>Prognostic implications of left ventricular hypertrophy and mechanical function in Fabry disease: A longitudinal cohort study</dc:title>
<dc:identifier>pmid:38704103</dc:identifier>
<dc:identifier>doi:10.1016/j.echo.2024.04.010</dc:identifier>
</item>
<item>
<title>Arterial transit artifacts and carotid plaque-RADS may predict symptoms in patients with carotid stenosis</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38703972/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: CBF, Plaque-RADS and ATAs were identified as independent risk factors for symptoms in patients with CAS and have a certain predictive value for symptoms, and the combined predictive value is greater, potentially providing a more effective imaging modality for clinical treatment and evaluation.</description>
<content:encoded><![CDATA[<div>Magn Reson Imaging. 2024 May 2:S0730-725X(24)00145-0. doi: 10.1016/j.mri.2024.05.001. Online ahead of print.ABSTRACTAIM: To analyze the correlation of carotid stenosis severity, the Plaque Reporting and Data System (RADS) score, arterial transit artifacts (ATAs), and cerebral blood flow (CBF) with clinical cerebral ischemic symptoms in patients with carotid artery stenosis (CAS).MATERIALS AND METHODS: Sixty-one patients with unilateral internal carotid artery stenosis or occlusion (≥50% stenosis) diagnosed by ultrasound, Computed Tomography(CT) angiography, or Magnetic Resonance(MR) angiography in Yichang City Central People's Hospital from January 2022 to February 2024 were retrospectively enrolled and divided into two groups according to the presence or absence of symptoms. Both groups underwent MR plaque imaging and arterial spin labeling (ASL)-based 3.0 T MRI to compare the differences in stenosis degree, Plaque-RADS score, ATA grade, and CBF between the two groups. Binary regression analysis was used to identify the parameters with statistically significant differences between the two groups and to evaluate their diagnostic efficacy using the area under the workup curve of the subjects.RESULTS: The Plaque-RADS score, ATA grade, and CBF differences in the anterior cerebral artery(ACA)blood supply region were correlated with symptoms, and the areas under the ROC curves for the CBF differences in the ACA blood supply region, Plaque-RADS score, ATA grade and a joint model that combines all three to predict symptoms in CAS patients were 0.672, 0.796, 0.788 and 0.919, respectively.CONCLUSIONS: CBF, Plaque-RADS and ATAs were identified as independent risk factors for symptoms in patients with CAS and have a certain predictive value for symptoms, and the combined predictive value is greater, potentially providing a more effective imaging modality for clinical treatment and evaluation.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703972/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38703972</a> | DOI:<a href=https://doi.org/10.1016/j.mri.2024.05.001>10.1016/j.mri.2024.05.001</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38703972</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Juan Xia</dc:creator>
<dc:creator>Chengxin Yu</dc:creator>
<dc:creator>Liang Li</dc:creator>
<dc:creator>Junlong Pan</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Magnetic resonance imaging</dc:source>
<dc:title>Arterial transit artifacts and carotid plaque-RADS may predict symptoms in patients with carotid stenosis</dc:title>
<dc:identifier>pmid:38703972</dc:identifier>
<dc:identifier>doi:10.1016/j.mri.2024.05.001</dc:identifier>
</item>
<item>
<title>Sex Specific Outcomes After Ischemic Stroke</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38703877/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>N/A.</description>
<content:encoded><![CDATA[<div>J Stroke Cerebrovasc Dis. 2024 May 2:107754. doi: 10.1016/j.jstrokecerebrovasdis.2024.107754. Online ahead of print.ABSTRACTN/A.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703877/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38703877</a> | DOI:<a href=https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107754>10.1016/j.jstrokecerebrovasdis.2024.107754</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38703877</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Fransisca Indraswari</dc:creator>
<dc:creator>Shadi Yaghi</dc:creator>
<dc:creator>Farhan Khan</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</dc:source>
<dc:title>Sex Specific Outcomes After Ischemic Stroke</dc:title>
<dc:identifier>pmid:38703877</dc:identifier>
<dc:identifier>doi:10.1016/j.jstrokecerebrovasdis.2024.107754</dc:identifier>
</item>
<item>
<title>Multicenter comparison using two AI stroke CT perfusion software packages for determining thrombectomy eligibility </title>
<link>https://pubmed.ncbi.nlm.nih.gov/38703875/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>CONCLUSIONS: Despite systematic differences in core and penumbra volume estimates between Viz.ai and RAPID.AI, DEFUSE-3 eligibility was not statistically different in primary or NIHSS subgroup analysis. A DEFUSE-3 eligibility difference, however, was seen on one scanner at one institution, suggesting scanner model and local CTP protocols can influence performance and cause discrepancies in thrombectomy eligibility. We thus recommend centers discuss optimal scanning protocols with software...</description>
<content:encoded><![CDATA[<div>J Stroke Cerebrovasc Dis. 2024 May 2:107750. doi: 10.1016/j.jstrokecerebrovasdis.2024.107750. Online ahead of print.ABSTRACTBACKGROUND: Stroke AI platforms assess infarcted core and potentially salvageable tissue (penumbra) to identify patients suitable for mechanical thrombectomy. Few studies have compared outputs of these platforms, and none have been multicenter or considered NIHSS or scanner/protocol differences. Our objective was to compare volume estimates and thrombectomy eligibility from two widely used CT perfusion (CTP) packages, Viz.ai and RAPID.AI, in a large multicenter cohort.METHODS: We analyzed CTP data of acute stroke patients with large vessel occlusion (LVO) from four institutions. Core and penumbra volumes were estimated by each software and DEFUSE-3 thrombectomy eligibility assessed. Results between software packages were compared and categorized by NIHSS score, scanner manufacturer/model, and institution.RESULTS: Primary analysis of 362 cases found statistically significant differences in both software's volume estimations, with subgroup analysis showing these differences were driven by results from a single scanner model, the Canon Aquilion One. Viz.ai provided larger estimates with mean differences of 8cc and 18cc for core and penumbra, respectively (p<0.001). NIHSS subgroup analysis also showed systematically larger Viz.ai volumes (p<0.001). Despite volume differences, a significant difference in thrombectomy eligibility was not found. Additional subgroup analysis showed significant differences in penumbra volume for the Phillips Ingenuity scanner, and thrombectomy eligibility for the Canon Aquilion One scanner at one center (7% increased eligibility with Viz.ai, p=0.03).CONCLUSIONS: Despite systematic differences in core and penumbra volume estimates between Viz.ai and RAPID.AI, DEFUSE-3 eligibility was not statistically different in primary or NIHSS subgroup analysis. A DEFUSE-3 eligibility difference, however, was seen on one scanner at one institution, suggesting scanner model and local CTP protocols can influence performance and cause discrepancies in thrombectomy eligibility. We thus recommend centers discuss optimal scanning protocols with software vendors and scanner manufacturers to maximize CTP accuracy.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703875/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38703875</a> | DOI:<a href=https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107750>10.1016/j.jstrokecerebrovasdis.2024.107750</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38703875</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin T Alwood</dc:creator>
<dc:creator>Dawn M Meyer</dc:creator>
<dc:creator>Chip Ionita</dc:creator>
<dc:creator>Kenneth V Snyder</dc:creator>
<dc:creator>Roberta Santos</dc:creator>
<dc:creator>Lindsey Perrotta</dc:creator>
<dc:creator>Ryan Crooks</dc:creator>
<dc:creator>Kimberlee Van Orden</dc:creator>
<dc:creator>Dolores Torres</dc:creator>
<dc:creator>Briana Poynor</dc:creator>
<dc:creator>Nhan Pham</dc:creator>
<dc:creator>Sophie Kelly</dc:creator>
<dc:creator>Brett C Meyer</dc:creator>
<dc:creator>Divya S Bolar</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</dc:source>
<dc:title>Multicenter comparison using two AI stroke CT perfusion software packages for determining thrombectomy eligibility </dc:title>
<dc:identifier>pmid:38703875</dc:identifier>
<dc:identifier>doi:10.1016/j.jstrokecerebrovasdis.2024.107750</dc:identifier>
</item>
<item>
<title>Myocardial ischemia-reperfusion injury released cellular fibronectin containing domain A (CFN-EDA): A destructive positive loop amplifying arterial thrombosis formation and exacerbating myocardial reperfusion injury</title>
<link>https://pubmed.ncbi.nlm.nih.gov/38703585/?utm_source=Feedvalidator&utm_medium=rss&utm_campaign=None&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&fc=None&ff=20240507172821&v=2.18.0.post9+e462414</link>
<description>Previous research has identified intravascular platelet thrombi in regions affected by myocardial ischemia-reperfusion (MI/R) injury and neighbouring areas. However, the occurrence of arterial thrombosis in the context of MI/R injury remains unexplored. This study utilizes intravital microscopy to investigate carotid artery thrombosis during MI/R injury in rats, establishing a connection with the presence of prothrombotic cellular fibronectin containing extra domain A (CFN-EDA) protein....</description>
<content:encoded><![CDATA[<div>Thromb Res. 2024 Apr 30;238:117-128. doi: 10.1016/j.thromres.2024.04.026. Online ahead of print.ABSTRACTPrevious research has identified intravascular platelet thrombi in regions affected by myocardial ischemia-reperfusion (MI/R) injury and neighbouring areas. However, the occurrence of arterial thrombosis in the context of MI/R injury remains unexplored. This study utilizes intravital microscopy to investigate carotid artery thrombosis during MI/R injury in rats, establishing a connection with the presence of prothrombotic cellular fibronectin containing extra domain A (CFN-EDA) protein. Additionally, the study examines samples from patients with coronary artery disease (CAD) both before and after coronary artery bypass grafting (CABG). Levels of CFN-EDA significantly increase following MI with further elevation observed following reperfusion of the ischemic myocardium. Thrombotic events, such as thrombus formation and growth, show a significant increase, while the time to complete cessation of blood flow in the carotid artery significantly decreases following MI/R injury induced by ferric chloride. The acute infusion of purified CFN-EDA protein accelerates in-vivo thrombotic events in healthy rats and significantly enhances in-vitro adenosine diphosphate and collagen-induced platelet aggregation. Treatment with anti-CFN-EDA antibodies protected the rat against MI/R injury and significantly improved cardiac function as evidenced by increased end-systolic pressure-volume relationship slope and preload recruitable stroke work compared to control. Similarly, in a human study, plasma CFN-EDA levels were notably elevated in CAD patients undergoing CABG. Post-surgery, these levels continued to rise over time, alongside cardiac injury biomarkers such as cardiac troponin and B-type natriuretic peptide. The study highlights that increased CFN-EDA due to CAD or MI initiates a destructive positive feedback loop by amplifying arterial thrombus formation, potentially exacerbating MI/R injury.PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703585/?utm_source=Feedvalidator&utm_medium=rss&utm_content=1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib&ff=20240507172821&v=2.18.0.post9+e462414">38703585</a> | DOI:<a href=https://doi.org/10.1016/j.thromres.2024.04.026>10.1016/j.thromres.2024.04.026</a></div>]]></content:encoded>
<guid isPermaLink="false">pubmed:38703585</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Moh Uzair</dc:creator>
<dc:creator>Chahak Singhal</dc:creator>
<dc:creator>Azeem Ali</dc:creator>
<dc:creator>Sangam Rajak</dc:creator>
<dc:creator>Aditya Kapoor</dc:creator>
<dc:creator>Surendra Kumar Agarwal</dc:creator>
<dc:creator>Swasti Tiwari</dc:creator>
<dc:creator>Shantanu Pande</dc:creator>
<dc:creator>Prem Prakash</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>Thrombosis research</dc:source>
<dc:title>Myocardial ischemia-reperfusion injury released cellular fibronectin containing domain A (CFN-EDA): A destructive positive loop amplifying arterial thrombosis formation and exacerbating myocardial reperfusion injury</dc:title>
<dc:identifier>pmid:38703585</dc:identifier>
<dc:identifier>doi:10.1016/j.thromres.2024.04.026</dc:identifier>
</item>
</channel>
</rss>

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):

<a href="http://www.feedvalidator.org/check.cgi?url=http%3A//www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi%3Frss_guid%3D1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib"><img src="valid-rss-rogers.png" alt="[Valid RSS]" title="Validate my RSS feed" /></a>

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=http%3A//www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi%3Frss_guid%3D1vGIiL00qKeT4_BrQf0tnV0RbCw41XEP22XBMPcA09_yeH4Yib

Home · About · News · Docs · Terms